, pub-4214183376442067, DIRECT, f08c47fec0942fa0
23.2 C
New York
Saturday, May 27, 2023

Translating phage remedy into the clinic: Latest accomplishments however persevering with challenges


“The phenomenon of bacteriophagy, as carried out underneath optimum situations in vitro, is spectacular. [1]

Science’s consciousness of the bacteriophage (phage) phenomenon appears to have begun by round 1898 [24], though the concept was not nicely appreciated till Felix d’Hérelle’s seminal phage paper of 1917 [5,6]. Though later it was prompt that d’Hérelle had the truth is been scooped by Frederick Twort in 1915 [7,8], then, in addition to immediately, each Twort and d’Hérelle are acknowledged as bacteriophage co-discoverers [9]. Previous to 1915, along with Gamaleya’s 1898 report, it’s doable that a lot of extra researchers had additionally found phage-associated phenomena, an inventory that notably mustn’t embrace the a lot referenced Hankin, 1896 [10,11]. In any case, it seems to have been quickly apparent to d’Hérelle that an entity able to killing micro organism—on the time a key defining attribute of phages together with their smallness and transmissibility—may have medical utility. Thus was born the idea of phage remedy [12], the therapy of bacterial infections with viruses (phage virions) to eradicate or not less than scale back numbers of disease-causing micro organism [13,14], with 1921 being the 12 months {that a} human phage remedy examine was first revealed [15].

Nonetheless, phage remedy doesn’t presently function a typical of care in most international locations. To discover why that’s so, this Essay begins by introducing fundamental bacteriophage biology, among the post-1921 historical past of phage remedy, and likewise a number of benefits related to utilizing phages as antibacterial brokers. We then flip to the rising catalog of latest scientific phage remedy successes, discussing the overall nature of those research specifically, in addition to vital future instructions. Regardless of these successes, a number of obstacles to the additional improvement, acceptance, and approval of phage remedy live on, which we differentiate into organic hurdles to distinction with these we dub as an alternative as “societal.” General, though we spotlight the growing potential for phages to function options or adjuncts to antibiotic remedy for bacterial illnesses, we emphasize the remaining challenges to creating this promising expertise extra clinically obtainable. For a complementary latest evaluation emphasizing a number of extra features of phage remedy not lined right here, we level the reader to Strathdee and colleagues [16].


“…le microbe antidysentérique est un bactériophage obligatoire. [5]

Bacteriophages, initially, are viruses of Micro organism, sharing the world with viruses of Archaea and viruses of area Eukarya. An alternate ecological categorization separates those who infect primarily “macro”-organisms (animals, crops, macrofungi, and bigger multicellular algae) from those who infect microorganisms (micro organism, archaea, single-celled protists, micro-fungi, and microscopic algae) [17,18]. For the latter, virus dissemination between particular person cells (e.g., between bacterial cells) and between complete organisms (additionally, e.g., between bacterial cells) are roughly the identical factor. For the viruses of macro-organisms, particularly multicellular organisms, dissemination as an alternative is inside our bodies, whereas transmission to new people, together with to different people, usually is a considerably distinct phenomenon [19]. Within the following part, we evaluation some phage remedy–related features of phage biology.

Tailed phages

Phages lately have been differentiated into quite a few taxa—notably households and genera but in addition subfamily ranks—as primarily based on genomic similarities between isolates [20]. Extra historically, not less than 10 distinct phage varieties have been distinguished on the premise of gross virion morphologies [21,22]. These morphologies range by way of whether or not or not virions comprise lipids, have tails, or comprise DNA or RNA genomes, in addition to whether or not these genomes are single-stranded or double-stranded. Smaller-genomed phages (underneath roughly 10 kb) typically possess single-stranded nucleic acid (DNA or RNA), middle-sized genomed phages (additionally RNA or DNA, however double stranded, and with genomes ranging in dimension from roughly 10 to fifteen kb) appear to usually have virions that comprise lipids, whereas larger-genomed phages (typically higher than 15 kb) seem to lack these lipids, have double-stranded DNA genomes, and possess tails [17,23,24]. It’s tailed phages, members of virus order Caudovirales (to get replaced with class Caudoviricetes; [20]), that characterize a lot of the phages employed in remedy.

The virion-productive life cycle of all tailed phages ends in lysis of the host bacterium, initiating an extracellular seek for new micro organism to contaminate [25] (Fig 1). This lysis breaches the bacterial cell envelope, thereby additionally metabolically destroying the phage-infected bacterium. Alternatively, many phages can show lysogenic cycles [26,27], which aren’t virion productive however throughout which the phage genome, now referred to as a “prophage,” nonetheless replicates together with its bacterial host. Lysogenic cycles brought on by tailed phages can ultimately give rise to lytic infections, therefore the time period, “lysogenic,” the place “lysogenic” is taken into account to be a property of lysogens (i.e., of micro organism harboring prophages). The phages able to establishing lysogenic cycles must be described as temperate [28].


Fig 1. Phage lytic an infection cycle.

The phage an infection cycle. This flows counterclockwise within the determine, ranging from the higher left. (1) Phage attachment to receptor molecules discovered on micro organism [29,30] is often described as processes of virion adsorption [31,32] with uptake involving motion of the virion genome from the phage virion into the bacterial cytoplasm. This will result in the famous lysogenic cycles (primary textual content) or, in some circumstances as an alternative, pseudolysogeny [3335], however as proven, notably for virulent phages, offers rise to lytic cycles. (2) Synthesis is of phage-specific macromolecules together with RNA, DNA, and proteins. Meeting is the method of technology of recent virions from these macromolecules as ensuing, finally, in (3) maturation of virions into adsorption proficient entities. (4) The timing of liberation of virions typically is underneath phage genetic management [36], although for sure varieties of phages (not tailed and likewise not proven), this launch happens chronically fairly than lytically [25].

Professionally lytic bacterial viruses

Throughout lysogenic cycles, temperate phages defend their bacterial hosts from being lysed by different, associated phages. This sort of safety is named superinfection immunity [37,38]. Though an infection of a bacterium by a temperate phage can, and infrequently does, end result instantly in a lytic cycle [39], these phages, not less than in unmodified kinds [40], should not typically thought to be helpful therapeutically. This typical absence from phage remedy use is because of each their lysogenic cycles (temperate phages thereby not at all times killing the micro organism they efficiently infect) and the famous superinfection immunity (stopping different phages from killing those self same micro organism). An extra issue is so-called lysogenic conversion [41], whereby many temperate phages encode bacterial virulence components (e.g., these liable for the intoxications related to cholera, diphtheria, and Escherichia coli O157:H7) [42,43].

Though many and even most viruses of archaea are additionally tailed [44], archaeal viruses typically should not described as phages [45]. Archaeal viruses have additionally been solely minimally explored for doable therapeutic makes use of [46], owing not less than partly to the relative dearth of archaea which can be related to illness [4749]. Viruses of protists are additionally not described as phages, though these viruses too have been proposed for doable therapeutic use [4951]. In contrast, the usage of bacteriophages, and particularly tailed bacteriophages, as therapeutic brokers has been intensive. This Essay thus focuses on the therapeutic use of bacterial viruses which can be mostly tailed, not less than ideally lack a capability to enter into lysogenic cycles (thereby being described as an alternative as strictly lytic, obligately lytic, or virulent), and that don’t encode bacterial virulence components. Wild-type phages possessing these properties, notably ones which can be unrelated to temperate phages, will be described as “professionally lytic” [28], and people are the popular phages for therapeutic use.

Historical past and benefits of phage remedy

“Quickly after Félix d’Hérelle found bacteriophages in affiliation with diarrheal diseases, he speculated that phages have been liable for the standard restoration from such illness by way of their antibacterial motion in vivo. [52]

Traditionally, the interpretation of phage remedy from the bench to the clinic has occurred at a fast tempo. That is partly as a result of techniques for testing new therapeutics weren’t as nicely developed 100 years in the past as they’re immediately. As well as, at the moment, there have been few different approaches to responding to the good deal of morbidity and mortality related to bacterial infections [53]. It was subsequently a lot simpler to justify scientific phage therapies with out prior, detailed preclinical knowledge. Confidence in phage utility was additionally seemingly fueled by a lot of apparently profitable anecdotal outcomes [54]. Moreover, phage remedies appeared protected, leading to minimal downsides for his or her scientific use, as will be notably true in fashionable occasions with the usage of purified phages for remedies [5558]. Thus, in a pre-antibiotics world, wherein customary of take care of therapy of bacterial infections was extremely missing in efficacy, phages with their inherent antibacterial properties may provide a a lot wanted hope. This doesn’t imply that phage remedy was extraordinarily extensively practiced within the Twenties and Nineteen Thirties. Nonetheless, there may be ample proof of their scientific use throughout this time, as a lot of historic opinions have documented [12,54,5965]. See Fig 2 for a timeline of notable phage therapy-impacting occasions.


Fig 2. Milestones in phage science and phage remedy.

Milestones in phage science and phage remedy. Abbreviations embrace GMP, good manufacturing observe; IV, intravenous; JAMA, Journal of the American Medical Affiliation. Early common references embrace [6668] and [1,69]. Extra references used to create the determine embrace from 1963 [70], 1987 [71], 2001 [72], 2008 [73], 2009 [74], 2012 [75], and 2021 [76]. Icon copyright attributions by first-use 12 months (all as obtained by way of and offered parenthetically; superscripts are related nation abbreviations): 1896 (Studio 365 TH), 1889 (pongsakorn TH), 1912 (Luiz Carvalho BR), 1919 (Sergey Demushkin RU), 1920 (Arafat Uddin BD), 1923 (Wuppdidu DE), 1929 (Irfan Setiawan ID), 1931 (Adrien Coquet FR), Nineteen Thirties (Mourad Mokrane RU), 1939 (Soremba DE), 1940 (Cassandra Cappello CA), 1942 (Icon Lauk ID), Nineteen Forties (WEBTECHOPS LLP IN), 1963 (Adrien Coquet FR), 1976 (Eko Purnomo ID), 1982 (One Pleasure ID), 2001 (Kelsey Armstrong US), 2006 (Nendra Wahyu Kuncoro ID), 2008 (Artistic Stall), 2009 (Kamin Ginkaew TH), 2018 (Kamin Ginkaew TH), 2019 (Wikimedia Commons), 2019 (Irfan Setiawan ID), 2020 (Wikimedia Commons), 2021 (Irfan Setiawan ID).

Phases of phage remedy improvement and enzybiotics

We are able to take into account the historic improvement of phage remedy by way of phases or intervals. Particularly in North America, we are able to distinguish these completely different phases into what Summers [59] described as “Enthusiasm,” the Twenties by way of the early Nineteen Thirties [6668]; “Skepticism,” the mid-Nineteen Thirties by way of the mid-Nineteen Forties, culminating within the widespread introduction of antibiotics; “Abandonment,” the mid-Nineteen Forties by way of the mid-Nineties [77]; after which “Latest curiosity,” which started within the mid-Nineties [64]. English language-published human research throughout this revival of curiosity quantity not less than 100 [78,79], and certainly we’re conscious of roughly 50 which were revealed in simply the 2020s. You will need to acknowledge, nonetheless, that phage remedy has been constantly practiced for nearly its whole historical past in numerous areas worldwide, equivalent to within the Soviet Union and its successor republics [75,80], but in addition now for a lot of a long time notably in Poland [71,80,81].

Extra lately, bacteriophage-derived antibacterial enzymes, additionally referred to as “enzybiotics,” have raised curiosity as a result of their usually fast and distinctive modes of motion together with their excessive specificity [82,83]. They’re proteinaceous—though in contrast to complete phages, they’re missing in nucleic acids, thus simplifying their regulation—and, importantly, are sometimes related to a low propensity for micro organism to develop resistance. Two lessons of phage-derived enzymes are generally described: peptidoglycan hydrolases (additionally known as “lysins”), which degrade the bacterial cell wall, and polysaccharide depolymerases, which break down bacterial surface-associated polysaccharides. The latter’s targets can embrace bacterial capsules, slime layers, biofilm matrix, and lipopolysaccharide (LPS) [82,8486]. These phage-derived enzybiotics have confirmed to be extremely efficient in animal fashions towards gram-positive micro organism and, particularly in modified kinds within the case of lysins, additionally towards gram-negative pathogens. A number of scientific trials have concerned lysins [82].

Benefits of phage remedy

The inherently bactericidal nature of particularly obligately lytic phages just isn’t the one attribute that makes phages helpful as antibacterial therapeutic brokers [8789]. Curtright and Abedon [90], e.g., tried to distinguish the advantages of utilizing phages to deal with bacterial infections into ones with higher or lesser utilities. Amongst higher utilities, along with their bactericidal nature, are the potential for phages to duplicate to larger doses in situ (auto-dosing), which may serve to counter processes of virion dilution and inactivation additionally in situ; the inherently low toxicity of professionally lytic phages, leading to phage remedy typically being a protected method to treating bacterial infections [5658,9193]; and a typical lack of cross-resistance between phages and antibiotics, though there are exceptions to the latter [9496]. Phages with novel antibacterial actions and low toxicities additionally are usually simply found. An extra benefit is that of restricted phage affect on microbiomes, in addition to the truth that reductions in bacterial performance (antagonistic pleiotropies) are sometimes related to mutations to phage resistance; each of those latter utilities of phage remedy are briefly mentioned in subsequent sections. Given the usefulness of phages as bacterial brokers that stem from these quite a few benefits, not solely have phages been employed to deal with bacterial infections for greater than a century, however phages are more and more getting used clinically particularly to deal with antibiotic resistant or tolerant infections.

Latest phage remedy accomplishments

“The thrill concerning the prospects of phage remedy (PT) has been rising worldwide, fueled by the latest experiences of its profitable software in extreme circumstances of bacterial infections. [13]

An increase in phage remedy scientific experiences is noticeable ranging from 2018. This represents a landmark 12 months for the rising implementation of contemporary phage remedy (“latest curiosity”), leading to vital new English language proof of scientific phage remedy efficacy. Numerically, whereas solely 2 scientific experiences have been revealed in 2015, 1 in 2016, and 5 in 2017, this rises to 13 in 2018, 16 in 2019, and 11 in 2020 [78]. Our as-yet much less formal counts in 2021 and 2022 additional point out that these numbers have risen once more to roughly 20 every.

Many of those newer, scientific phage remedy experiences have been case research or case collection carried out as compassionate remedies [91,97,98]. These thereby lack detrimental therapy management populations and have been deemed as possessing “low-to-moderate high quality, with excessive threat of bias and huge heterogeneity” [99]. Specialists nonetheless agree, nonetheless, that these research can assist claims of phage remedy security [5658,91,93], with this security having been demonstrated even in populations of critically in poor health sufferers with extreme sepsis and septic shock [56,100,101]. However, it is very important take into account that the first goal of compassionate remedies is to offer therapeutic advantages to particular person sufferers fairly than to judge the efficacy of the therapy itself. It has been argued additionally that profitable phage remedy case experiences and collection, and naturally additionally profitable scientific efficacy trials, will be considered in a optimistic gentle supporting an observance of phage remedy anti-infection effectiveness [102].

Taking into account these limitations, in addition to the small pattern sizes of those research—a majority are single case experiences and just a few are case collection—and likewise the character of the research (i.e., uncontrolled trials), we focus on under consultant experiences of scientific enhancements throughout and after use of phage remedy, highlighting in Fig 3 latest research that notably counsel a possible scientific efficacy of phage remedy. This subject has been extensively reviewed in latest papers [16,78,91,103], however key features that we take into account right here additional are the primary use of genetically engineered (GMO-like) phages to deal with infections, implementation of systematic analyses of phage remedies, and the rise of customized phage remedy together with extra standardized monitoring on this period of precision drugs.

Rise of customized phage remedy and standardized monitoring

The idea of customized or bespoke phage remedy could also be considered as “a paradigm shift within the improvement and software of infectious illness therapeutics” [125]. Certainly, a majority of scientific research have described the usage of rigorously chosen and exactly focused phages which were included into remedies on a patient-by-patient foundation. Often known as “magistral phage” [126] (or magistral phages; [127]), a brand new, pragmatic regulatory framework is being pioneered by a multidisciplinary phage activity power in Belgium (the Coordination group for Bacteriophage remedy Leuven or CBL) made up of phage scientists, pharmacists, and clinicians, and which importantly has been supported by educated authorities (e.g., the Federal Company for Medicines and Well being Merchandise in Belgium). Assortment of affected person and scientific knowledge in standardized manners, additional enlargement of phage banks (collections of potential therapeutic phages), and optimization of phage remedy protocols are the principle ideas endorsed within the examine protocol, referred to as PHAGEFORCE [128], which many different international locations in Europe and past have began to comply with [129].

Wonderful consensus paperwork have additionally lately emerged from Europe [128] and america of America [130] that deal with the necessity to standardize and monitor phage remedies with a view to higher perceive phage remedy, particularly inside this context of customized phage remedy. An identical degree of standardization was beneficial by Australian Infectious Ailments physicians in an off-the-cuff survey and is mirrored within the worldwide efforts to arrange a phage remedy affected person database (generally known as “Worldwide Phagistry”) for centralized monitoring of affected person circumstances in addition to standardized, unbiased reporting to make sure optimum remedies (private communication, S. McCallin, L. Leitner, et al.). This has resulted in a extra constant method to therapy and monitoring of phage remedy, acknowledging variations in focused etiologies and routes of phage administration, however specializing in course of, security, and monitoring [129].

Whereas vital hurdles stay to be addressed, the present use of phage remedy and nonetheless considerably casual however enhancing proof of its efficacy counsel that phage remedy seemingly might be launched to the mainstream particularly as a personalised drugs. Using the abovementioned standardized and multidisciplinary approaches will assist determine and deal with main scientific and therapy hurdles for furthering the acceptance of phage remedy within the context of customized drugs, but in addition assist to enhance the design of randomized managed trials.

Genetic engineering of therapeutic phages

Engineering can improve the therapeutic potential of bacteriophages [76,131133]. This may be achieved immediately by way of alteration of host vary (e.g., by way of homologous recombination or mutagenesis of tail fiber genes) [134136], modification of the phage an infection (e.g., by way of deletion or deactivation of genes required for lysogenic cycles) [137,138], or modification of the phage capsid (e.g., by way of choice of phages able to remaining within the circulatory system for longer occasions) [139,140]. Phages will also be modified to boost the antibacterial exercise of standard antibiotics, equivalent to by engineering into them a capability to provide quorum sensing–interfering components [141] or the famous biofilm-matrix degrading enzymes [142]. Because the inception of molecular biology, these and a lot of different strategies have been developed to engineer phages, approaches which were lately reviewed in a phage remedy context [16].

A breakthrough examine by Dedrick and colleagues [40], in 2019, described the primary revealed scientific software of genetically modified phages to deal with a clinically disseminated an infection brought on by the notoriously antibiotic-resistant Mycobacterium abscessus. For this case examine, 1 naturally obligately lytic phage (phage Muddy) and a couple of temperate phages (BP and ZoeJ) have been recognized that might successfully kill the scientific isolate, ranging from a library of over 1,800 phages. To generate a therapeutic cocktail, the authors employed a Bacteriophage Recombineering of Electroporated DNA (BRED) approach [143] to take away lysogenization modules from the two temperate phages. The next phage remedy course of seven months, which included each topical and intravenous administration of the tailored phage cocktail, was reported to be nicely tolerated and resulted in important scientific enchancment. An additional narrative of the case will be discovered right here: [144]. This examine was then adopted by a case collection involving the phage therapy of 20 extra sufferers, additionally together with use of genetically engineered phages, additional demonstrating each their security and effectiveness as antimycobacterial brokers [122].

It thus has solely been up to now few years that genetically engineered phages have been employed clinically to deal with bacterial infections, focusing on solely a single bacterial genus (Mycobacterium) and used for compassionate care (additionally see dialogue in [76]). Fastidiously designed and managed scientific trials are subsequently nonetheless wanted to provide definitive solutions on the potential for phage genetic engineering to enhance therapies, as can also be the case with conventional phage remedy involving pure phages. Phage engineering guarantees to generate therapeutics with distinctive properties, nonetheless, thereby providing different therapy approaches within the administration of difficult-to-treat bacterial infections together with a possible for stronger patent safety (under).

Systematic analyses of scientific research

Whereas the protection of phage remedy has been demonstrated in additional than 50 research carried out since 2000 [58], systematic analyses of scientific and microbiological phage remedies are comparatively scarce. Most revealed scientific phage remedies have concerned sufferers handled on compassionate grounds, which restricts the gathering and systematic evaluation of scientific knowledge. Furthermore, the restricted sizes and heterogeneity of reported research (e.g., numerous pathologies, use of various single phages or as an alternative phage cocktails, and completely different administrations protocols) makes it virtually unattainable to conduct strong meta-analyses. Nonetheless, 2 latest systematic analyses have been carried out reporting favorable scientific and microbiological outcomes attributed to adjunctive phage remedy in not less than 60% of handled sufferers [56,122].

In 2020, a examine carried out as a single-arm, noncomparative trial explored the protection and tolerability of phage remedy in 13 severely in poor health sufferers with S. aureus bacteremias, together with infective endocarditis [56]. A scientific evaluation was carried out of bacterial and phage kinetics within the blood in addition to inflammatory responses. As well as, the microbiological outcomes have been assessed by way of comparative whole-genome sequencing evaluation of bacterial isolates collected earlier than introduction of phage remedy, in addition to any isolates retrieved throughout phage remedy, to make sure that no phage resistance developed in vivo. To our data, this examine was the primary of its variety to offer a complete and multimodal evaluation (together with scientific, microbiological, and immunological assessments) of critically in poor health sufferers present process phage therapy.

In 2022, a case collection involving 20 sufferers with non-tuberculosis Mycobacterium infections reported security and tolerability of phage remedy, utilizing the famous pure and genetically modified phages [122]. The authors carried out microbiological and immunological monitoring of sufferers, and, though the examine was carried out on compassionate foundation, it offered helpful perception that ought to function a fundament for design of future randomized managed trials within the area.

Persevering with challenges for phage remedy

“However the intensive want, curiosity, expertise and reported successes of phage remedy, typical western approaches to biomedical analysis and implementation are poorly tailored to inspire, regulate or assess such nonstandard approaches to antibacterial remedy. [145]

Phages not solely supply quite a few benefits as antibacterial therapies but in addition, regardless of their ongoing and growing use for treating bacterial infections for which antibiotics should not or now not helpful, current a lot of challenges to their elevated software. These challenges embrace problems with limitations to phage host ranges and thereby spectra of exercise, the potential for improvement of bacterial resistance to phages, doable detrimental impacts of antibiotics on phage performance, therapy phage-mediated transduction of bacterial DNA, interactions with the immune system, regulatory points, uncommon pharmacology, inadequate consciousness of phages as therapeutic antibacterial brokers, and the potential for phage remedy skepticism (Fig 4). We differentiate these issues into organic or as an alternative societal challenges. Extra problems embrace these associated to manufacturing and storage of therapeutic phages, however we refer readers as an alternative to [146,147] for dialogue of these points.

Organic challenges

Though obligately lytic phages are inherently bactericidal, that doesn’t imply that their existence as potential antibacterial brokers is with out limitations. Many of those points, together with phage-induced bacterial lysis, are features of the pharmacodynamics of phage remedy, notably treatment-phage affect on micro organism but in addition their impact on handled our bodies [148]. Although offered as ongoing challenges to the implementation of phage remedy, these organic points should not essentially inevitably negatively impactful on the potential for profitable remedies, notably given prior data of their existence.

Host vary limitations.

The host ranges of phages are usually comparatively slim, usually consisting of solely a subset of strains inside a single bacterial species [149,150]. Certainly, an usually said advantage of phage remedy is the ensuing considerably slim spectrum of exercise, notably in comparison with most commercially obtainable antibiotics. It is because therapy phages have a lowered potential to provide rise to antagonistic results as a result of an solely minimal detrimental affect on useful, nontarget commensal micro organism [111,151154]. Disadvantages, nonetheless, can include this restricted phage spectrum of exercise, and these are not less than 2-fold. First, it makes it tougher to deal with bacterial infections empirically when utilizing phages in contrast with broader-spectrum antibiotics. Second, it signifies that higher numbers of distinctive phage merchandise must be developed total, i.e., at a minimal one for each bacterial species to be focused.

A partial reply not less than to the primary concern (limitations on empirical therapy), however in some circumstances to the second as nicely (not less than 1 formulation per bacterial species focused), is the event of what are generally known as phage cocktails [155157]. Cocktails are preparations that possess a number of phage varieties, ideally together with phages with completely different host ranges. If the species of a to-be-treated bacterial an infection has been decided, then it’s doable to make use of cocktails, which particularly goal that bacterial species. Alternatively, phage cocktails that concentrate on particular illness varieties fairly than simply particular person bacterial species can be utilized and have been notably in international locations of the previous Soviet Union, equivalent to these for wound-associated infections (a pyophage cocktail) or gastrointestinal infections (an intestiphage cocktail) [61,158160]. These are inclined to encompass a number of phages every focusing on a person bacterial species, and that is fairly than particular person phages as an alternative focusing on a number of bacterial species. Fairly than mixing completely different wild-type phages to generate phage cocktails, it’s doable as an alternative to switch the host ranges of present phage isolates both by phage evolution [161], also referred to as phage coaching [162], or by way of genetic engineering.

Bacterial resistance to phages.

It’s the nature of genetic entities to evolve, if they will, in response to environmental situations. That is abundantly true in response to chemotherapies, whether or not what’s being handled is irregular cell development inside our bodies or bacterial populations being uncovered to antibiotics. The identical is true for micro organism and phages [163]. We are able to differentiate resistance to phages or chemotherapies into that which is acquired and that which is inherent in a given bacterial species. Acquired resistance can, in flip, be differentiated into that which involves stably dominate bacterial inhabitants previous to publicity to an antagonist and that which as an alternative involves prominence solely as soon as publicity has begun, with the latter of curiosity right here particularly when ensuing from treatment-mediated selective pressures [148]. To each antibiotics and phages, we are able to distinguish additionally between resistance acquired horizontally, particularly in the middle of bacterial acquisition of cell genetic components [164,165], and that which is acquired mutationally, i.e., as leading to modification of bacterial molecules required by phages to efficiently infect [166]. Moreover, and likewise true for antibiotics, we are able to break up bacterial mechanisms that intrude with therapies into those who come up in otherwise-sensitive micro organism solely phenotypically (types of tolerance) and those who come up genetically (resistance) [167].

Mutations to phage resistance, specifically, can lead to antagonistic pleiotropies (trade-offs) [167]. These, typically talking, are phenotypes which can be related to particular person alleles that, on the one hand, present advantages to their service, equivalent to that of phage resistance by micro organism, however, then again, end in a price to their carriers. Such bacterial purposeful trade-offs could also be notably prevalent following phage therapies as a result of phages can profit by focusing on bacterial molecules which can be tough for micro organism to do with out. Examples of detrimental phenotypes related to phage-selected antagonistic pleiotropies can embrace lowered bacterial development charges, decreased bacterial virulence, or elevated bacterial sensitivity to antibiotics [168172]. Phage-resistant bacterial pathogens might, as a consequence, turn out to be diminished of their skill to proceed to trigger infections. See, too, the associated idea of “Directing phage-resistance evolution” [173].

Limitations to phage host ranges are a corollary of phage resistance, and each will be addressed by means of phage cocktails. This often is completed by combining phages with complementary host ranges to extend empirical protection for a single focused bacterial species. Utility of novel mixtures of antibiotics will also be justified towards growing empirical protection [174]. The widely decrease toxicities of phages, nonetheless, ought to allow the routine use of novel phage mixtures to deal with sufferers, not simply when addressing medical crises, i.e., whereas using untested mixtures of antibiotics to deal with sufferers must be tried solely underneath extra determined circumstances, provided that untried mixtures of medication can provide rise to sudden unintended effects, there exist few related obstacles to using new mixtures of particularly professionally lytic phages in phage cocktails. Certainly, there exists little expectation that novel phage–phage interactions will end in substantial and even essentially any anti-patient toxicities.

To make use of phage cocktails to restrict bacterial capacities to evolve resistance, it’s typically vital to incorporate inside cocktails not simply a number of phage varieties possessing complementary host ranges but in addition greater than 1 phage host vary kind that is ready to infect the focused bacterial pressure, and for which bacterial mutation to cross-resistance to each (or extra) cotargeting phages is of low chance. In different phrases, to scale back the potential for micro organism to evolve resistance to phages by using phage cocktails, it’s vital that cocktails possess a adequate “depth” of antibacterial exercise [155], with a depth of 1 being a single phage isolate inside a cocktail capable of kill a focused bacterium, a depth of two being 2 phage isolates inside a cocktail capable of independently goal, thereby with minimal cross resistance, that very same bacterium, and so forth. That is both along with or as an alternative of phage cocktails possessing substantial total breadth of host ranges (broader spectrum of exercise), i.e., as is required to raised guarantee not less than the preliminary success of empirical remedies fairly than essentially additionally inhibition of bacterial evolution of phage resistance [155].

Interactions with antibiotics.

As antibiotics characterize the usual of take care of therapy of bacterial infections, it’s inevitable that phage therapies will usually be undertaken as antibiotic cotherapies [78]. As is the case for antimicrobial remedies typically, we are able to count on the interactions between phages and antibiotics to vary from antagonistic to additive to synergistic. Antibiotic antagonism of phages particularly could also be anticipated, as antibiotics usually intrude with bacterial processes required for phage an infection success [175179]. As well as, the truth that antibiotics can scale back bacterial numbers on their very own will contribute to a lowered potential for phages to amplify themselves in situ [180]. It’s unknown, nonetheless, to what extent this in vitro–demonstrated antagonism truly impacts scientific remedies.

Alternatively, combining antibiotic and phage remedies can improve total effectiveness. So as of accelerating effectiveness, this may variously be described as involving facilitating, additive, or synergistic interactions [181]. These are, respectively, some however lower than additive will increase within the elimination of focused micro organism relative to every agent appearing alone (facilitative), every agent impacting micro organism independently of the opposite’s actions (additive), and higher than additive micro organism killing (synergism). Synergistic interactions between phages and antibiotics, particularly at subinhibitory antibiotic concentrations, also can end in what’s described as a phage-antibiotic synergy (PAS) [32,147,179,182,183]. With PAS, the presence of such low antibiotic doses truly enhances sure features of phage an infection, contrasting the famous potential for larger, inhibitory doses of antibiotics to antagonistically intrude with phage infections.

We are able to additionally differentiate whether or not phages together with antibiotics are more practical at merely clearing prone micro organism within the close to time period or, as an alternative, are more practical at interfering with the evolution of phage or antibiotic resistance over longer time frames. Close to-term enhancements might be related to PAS however also can end result from merely additive interactions, in addition to the famous facilitation. Long run, the standard lack of cross-resistance to phages and antibiotics ought to improve the variety of bacterial mutations required to realize full resistance to a mixed therapy [184,185]. That is the standard objective of mixture remedies [174,186189] together with the using of phage cocktails possessing greater-than-1 depths of exercise. Alternatively, acquisition of phage resistance can lead to micro organism changing into prone as soon as extra to antibiotic results (resensitization) [106,170,190,191]. However each the inevitability and potential utilities of mixing phages with antibiotics, the ensuing pharmacodynamics, notably when treating utilizing bacteria-inhibiting doses of particular antibiotics together with particular phages, stay considerably understudied.


Transduction is phage virion-mediated motion of non-phage DNA between micro organism [192]. It’s presumably problematic throughout phage remedies owing to the potential for phages to move bacterial virulence issue genes between completely different bacterial strains. This contains transporting antibiotic-resistance genes in addition to bacterial pathogenicity islands and bacterial plasmids [193196]. Transduction, nonetheless, is a definite phenomenon from lysogenic conversion [197], since transduction entails unintended and short-term virion packaging of bacterial DNA, in contrast with long-term carriage of bacteria-like genes by wild-type temperate phages (lysogenic conversion). There are 3 fundamental contexts in the middle of phage remedy the place transduction might be problematic: motion of DNA from the micro organism used to propagate therapeutic phages in vitro for subsequent therapeutic use; motion of DNA from nontarget micro organism to therapeutically focused micro organism; and motion of DNA from focused micro organism to nontargeted micro organism. The primary of those will be prevented by using micro organism for phage propagation that lack related virulence issue genes. The second and third will be lowered in chance by using therapeutic phages that possess sufficiently slim host ranges.

It is usually doable to easily keep away from utilizing phages which can be able to transducing bacterial DNA, i.e., by not utilizing so-called “transducing phages.” The latter embrace temperate phages, with their skill to maneuver small numbers of bacterial genes in what is named specialised transduction (although, once more, this isn’t equal to lysogenic conversion). Of in all probability higher relevance to phage remedy is avoidance of phages that bundle their DNA utilizing pac websites and headful genome packaging, each together with phages not considerably degrading the DNA of their host bacterium in the middle of lytic cycles [198]. Phages possessing these latter properties can act as generalized transducing phages, i.e., phages which can be capable of solely bundle bacterial DNA as much as roughly a phage genome dimension in size after which switch that DNA to new micro organism.

Of the organic challenges going through phage remedy, the potential for transduction nonetheless is usually thought of a lesser concern [199]. It is because transduction is a pure course of that occurs independently of any therapeutic introduction of phages and is usually related to temperate phages that are usually prevented for phage remedy independently of any transducing phage standing. Additionally, an in any other case untreated bacterial an infection can be of a lot higher quick detrimental affect. Thus, as famous by Ry Younger [200], “Until you’re fully compulsive, it doesn’t make an entire lot of sense to me to fret about transduction.”


In scientific settings, phage–micro organism dynamics develop along with strain from the mammalian host immune system, and this has usually been said as a considerable concern relating to the scientific implementation of phage remedy. Specifically, there are issues {that a} affected person’s immune standing will affect the effectiveness of phage therapies, but in addition that phage–immune system interactions may be dangerous to sufferers. Alternatively is the idea of “immunophage synergy,” as offered by Roach and colleagues [168], the place each neutrophils and phages have been vital for decision of acute pulmonary an infection in mice. Phages even have immunomodulatory properties, impacting the perform of main populations of immune cells that contribute to each innate and adaptive responses [201]. This contains, amongst different responses, cytokine manufacturing (completely different from LPS-induced cytokine profiles) [202], phagocytosis [203], the respiratory burst of phagocytic cells [204], and manufacturing of antibodies towards non-phage antigens [201]. Phages are additionally part of the conventional human microbiome [205], with some phage virions adhering to mucosal surfaces and thereby doubtlessly serving as a non-host–delivered layer of immunity [206208]. Thus, the function of the immune system in phage remedy seems to be multilayered and, certainly, in observe, is prone to be much less of a problem to phage remedy success however as an alternative an vital contributor to that success.

Phages will be discovered, specifically, within the human gastrointestinal tract, together with, e.g., these infecting Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria [207,209,210]. Phages thus characterize core elements of steady intestine microbiomes, and they’re consequently immunologically nicely tolerated by the physique. Persistently, in a latest case collection carried out on the Phage Remedy Unit on the Hirszfeld Institute in Poland, a majority of sufferers didn’t present noticeably larger ranges of anti-phage antibodies of their sera throughout oral and native phage cocktail therapy of methicillin-resistant S. aureus infections [211]. Even when the humoral immune response was higher, anti-phage antibody manufacturing didn’t appear to provide rise to unsatisfactory scientific outcomes. The depth of the anti-phage humoral response, nonetheless, might range relying on phage kind, its inherent immunogenicity, and the purity of a phage preparation [12,212]. Phage dosage, timing of remedies, routes of administration, and the immune standing of a affected person additionally might contribute to the affect of anti-phage humoral immunity on phage remedy success [201,213,214]. However, it is very important remember that anti-phage antibody manufacturing doesn’t essentially imply phage inactivation [201] because it additionally relies on antibody titers and specificity. One also can take into account choice or engineering of phages that might be extra immune to antibody-related inactivation [76,202].

An extra concern throughout phage remedy is that therapy of gram-negative pathogen infections with excessive phage dosages might result in a synchronized lysis of enormous numbers of bacterial hosts together with concomitant launch of endotoxin. This triggers irritation, usually by way of Toll-like receptor 4 pathways, in addition to fever and will trigger native ache [120]. However, this LPS launch doesn’t essentially exceed the quantities generated in the middle of antibiotic remedies [215], and a septic shock syndrome following phage therapy of those pathogens has not been reported. Certainly, it’s usually noticed in research that phage remedies are related to not more than minor antagonistic results, if any in any respect. Thus, issues which were expressed over the potential for the immune system to intrude with phage remedy efficacy seem to have been considerably exaggerated.

Societal challenges

Widespread implementation of nonstandard remedies by physicians requires not simply proof of efficacy but in addition regulatory approval, profitable advertising and marketing, and a willingness of these concerned to undertake such remedies. On this part, we take into account these extra, societal challenges to broader adoption of phage remedy, particularly by Western drugs.

Regulatory points.

Within the former Soviet Union, phages have been mass produced for remedy and have lengthy been obtainable, even over-the-counter [61,216], with the primary phage remedy trials there courting again to the Twenties [217]. Elsewhere, phage remedy has been obtainable virtually just for “compassionate use” [91,97,98] (i.e., when want is nice and all else has failed) and notably for therapy of pan-drug-resistant infections or in any other case following antibiotic therapy failures (i.e., with phages serving as salvage therapies). Regardless of the latest progress in lots of features of the event of phage remedy, the introduction of phages into the clinic nonetheless faces main obstacles [147,218,219], and that is notably from unresolved regulatory questions [220].

To maneuver ahead, both present laws will want substantial modification or new laws will must be proposed to cowl features of phage remedy that differ from these of conventional antibiotics. Laws, specifically, have to accommodate phage genetic malleability (their potential to evolve), their slim host vary, and their uncommon pharmacological properties. Each US and European regulatory authorities not less than agree, nonetheless, that therapeutic phages must be categorised as organic therapies [221], requiring compliance with pretty well-defined legislative, manufacturing, and manufacturing frameworks. Many consultants, together with regulatory authorities such because the US Meals and Drug Administration (FDA), additionally agree that proof of phage remedy efficacy from managed scientific trials, of which there to date have been solely a really restricted quantity, are important to speed up improvement of regulatory frameworks.

As a result of present laws have been developed for industry-scale manufacturing of medicines, they’re much less nicely suited to the extra customized approaches of phage remedy [147]. Inadequate flexibility and exemptions inside these frameworks, e.g., to permit for the introduction or substitution of recent phages into authorised preparations in response to resistance improvement, has had a chilling impact on market uptake and the in any other case widespread software of phages in therapies [222]. In Europe, authorities are making an effort to streamline the usage of customized phage therapies, with many international locations following Belgium’s pioneering method of regulated magistral phage preparations tailor-made in a context of compassionate take care of particular an infection and affected person circumstances [147,223]. Effectively previous to these efforts, the Hirszfeld Institute in Wrocław, Poland, has had a many decades-long historical past of involvement in customized phage remedy as too has been the case in and across the Eliava Institute in Tbilisi, Georgia [80,81].

Distinctive pharmacology.

An vital part of profitable regulatory approval of medication is a strong characterization of their related pharmacology. Examine of the pharmacology of phages has been considerably uncared for, nonetheless, owing to how lengthy traditionally phages have been used to deal with bacterial infections, which largely has predated the event of contemporary pharmacological examine, and likewise, arguably, because of the relative security of phage use as antibacterial brokers, which have made issues over potential toxicities considerably moot [148]. As well as, examine of the pharmacology of antibacterial brokers has largely been developed from a perspective of use of antibiotics. Thus, the problem of the individuality of phage use as antibacterial brokers will be considered as considerably of a societal assemble, i.e., had antibacterial pharmacology as a science been developed primarily based totally on the properties of phages fairly than these of antibiotics, then it presumably can be antibiotic pharmacology that’s “distinctive,” relative to phages, fairly than that of phages relative to antibiotics. This part thus offers an outline of phage remedy pharmacology and does so notably from a perspective of how phage remedy pharmacology differs from that of antibiotics. General, the problem on this case is to offer each regulatory companies and physicians with detailed analyses of phage pharmacokinetics (PK) throughout remedies.

Pharmacology will be thought of, specifically, alongside the normal divisions of PK and pharmacodynamics (PD), and that is true for phage remedy pharmacology as nicely [147,224,225]. PK refers to mechanisms that affect drug distribution to focus on tissues, together with to the neighborhood of focused micro organism, notably to end in drug concentrations which can be sufficient to realize results [226]. These results are described by the PD part of pharmacology, with essentially the most related PD impact being antibacterial exercise. It’s phage remedy PK that may differ considerably from that of different prescription drugs, whereas major phage remedy PD are conceptually much like different antibacterial brokers by way of the impact of killing micro organism. We subsequently focus right here particularly on the weird PK of phage remedy.

A drug’s PK will be broadly outlined by a handful of key identifiers. These embrace space underneath the curve (in situ focus as a perform of time) divided by minimal inhibitory focus (AUC/MIC), most drug in situ focus additionally divided by MIC (Cmax/MIC), and the fraction of time between dosings over which in situ drug concentrations exceed MIC (abbreviated as t>MIC). These key PK identifiers, nonetheless, haven’t been as nicely outlined for phages as they’ve been for antibiotics. That is, not less than partly, as a result of though a number of teams have used checkerboard-type assays to explain phage MICs [191,227229], there, nonetheless, is not any customary technique for outlining phage MICs and nor has there been strong in vivo validation [55].

Difficulties in defining phage remedy PK in addition to MICs stem largely from the potential for phages to proliferate throughout remedies. Compounding this complication, the extent of this in situ phage proliferation will are inclined to range with phage properties (notably as impacting the productiveness of their infections), the properties of focused micro organism, and the properties of the handled an infection itself (perfusions, immune components, adjunct antibiotic results, and so forth.). One other confounding variable is the famous PAS [147,179,182,183], the place particularly sub-MIC concentrations of sure antibiotics can increase phage manufacturing. Furthermore, titers of phage particles relative to concentrations of focused bacterial cells might enormously affect PK parameters, notably with these phage concentrations various nonlinearly over time in response to that ratio [230]. Additionally related is that reaching preliminary phage concentrations in a spread of 108 to 109 per ml (thereby presumably requiring much less in situ phage proliferation) could also be helpful towards reaching therapy success [55,56,58,225] and that phages can take a number of hours to achieve most concentrations, equivalent to within the blood, with that timing various with completely different routes of administration.

Particularly when phage proliferation is much less influential, then AUC and thereby phage remedy PK must be extra much like that of conventional prescription drugs. This must be seen notably with so-called passive remedies [224,231,232] the place dosed phage concentrations alone—like dosed antibiotic concentrations alone—must be excessive sufficient to kill a majority of focused micro organism, assuming sufficient bioavailability and distribution. An extra concern, related maybe particularly to the continuation of bacterial killing as soon as numbers of phage proliferation-supporting micro organism have considerably declined in concentrations, is that phage counts, like antibiotic concentrations, will are inclined to lower over hours following dosing [233236]. The charges of phage elimination of dosed phages from the physique (as one other vital PK identifier, outlined by way of half-life or t1/2) additionally might range with routes of phage administration [226,237].

The stage that an an infection is handled is one other important issue affecting phage remedy PK. Biofilm-resident micro organism, which are sometimes discovered later throughout continual bacterial infections [54], will be in much less energetic development states and range of their virulence [238], doubtlessly affecting their tolerance of phage remedies [167]. As well as, bacterial stationary phases can usually be antagonistic to productive phage lytic infections [34,239241] as can also inhibitory concentrations of antibiotics. It additionally will be tough to extrapolate from the in vitro exercise of any antibacterial agent, together with bacteriophages, to scientific outcomes, since host components together with an infection websites and kinds are each main therapy–consequence determinants however will are inclined to differ from affected person to affected person. Thus, phages can fail to resolve an an infection brought on by a pathogen even when these phages seem like powerfully energetic in vitro. Phage therapies, nonetheless, could also be extra promising than antibiotics in some circumstances within the therapy of biofilms [54,106,242,243].

Whereas phage remedy PK will be considerably tougher to outline than these of antibiotics, the in situ phage proliferation underlying a lot of that issue, i.e., phage auto-dosing, is probably going additionally a selected benefit of phage remedy. However, to realize constantly efficient phage remedies, routes and dosages of phage administration should be evaluated and standardized to every particular phage–host-infectious illness mixture [226,244,245]. Given the range of phages which can be or might be obtainable for phage remedy use, nonetheless, reaching such analysis and standardization on a phage-by-phage foundation may characterize a frightening obstacle to strong phage remedy scientific implementation.

Societal consciousness of phage remedy.

Belief in phages and phage remedy stays sturdy in former Soviet Union republics, notably Georgia and Russia [62,216]. Within the Western world, in distinction, appreciation of phage remedy has solely gained momentum in recent times, with a rising variety of circumstances highlighting efficacy in treating numerous multidrug-resistant infections. These vary from lung infections in sufferers with cystic fibrosis (CF) [40] to therapy of urinary tract infections [246] to decision of essentially the most extreme infections [247], together with phage use as remedies for gram-positive sepsis and septic shock [56]. Though most of this proof is anecdotal, experiences of phage remedy accomplishments have led to elevated media protection of phage remedy, fueling curiosity on this new therapeutic different among the many public. Although sadly not representing a phage remedy success, the story of Mallory Smith—a younger affected person with CF who died of a pan-drug-resistant lung an infection previous to the initiation of phage therapy [248]—specifically, has raised consciousness of the significance of phage remedy as a possible therapy possibility on this susceptible inhabitants.

There was a corresponding improve in funding for phage analysis and initiation of a lot of managed scientific trials within the area [78,93,103,130,144,147,249]. With cautious optimism, pioneers of contemporary phage remedy are establishing nationwide and worldwide initiatives the place fundamental scientists and clinicians can work collectively to professionalize phage remedy (Desk 1) through the use of well-defined and standardized therapy approaches [129], thereby including to the work of considerably extra established phage remedy models and facilities (notably these of Georgia and Poland). The last word goal of such initiatives is to raised align this therapeutic possibility with the priorities of primary funding and regulatory our bodies, clinics and pharmacopeia, and, lastly, of sufferers themselves. Alternatively, for an inventory of phage remedy in addition to merely phage-based business entities, see Phage Firms.

Physicians seem like taking part in much less of a job in driving the resurgence of curiosity in phage remedy. A survey from 2019 carried out within the largest Belgian hospital and largest phage remedy middle in Western Europe (Queen Astrid Army Hospital) indicated that greater than 70% of phage remedy requests got here from sufferers themselves or their relations and solely one-third or so from treating physicians [272]. This was attributed to a scarcity of inclusion of phage remedy in medical faculty curricula or, as one clinician defined [273], “Colleagues don’t know phages fairly than are against them,” and phage remedy in any other case is usually regarded by physicians as an “inaccessible chance.” Thus, consciousness of phages as potential remedies of bacterial infections definitely is rising however just isn’t practically common.

Phage remedy skepticism.

A considerably distinctive problem to the usage of phages as antibacterial brokers is a mix of their lengthy historical past and insufficiently well-documented efficacy. The previous allowed for the preliminary “enthusiasm” for phage use. Notably, their skill to focus on micro organism however not our personal tissues (selective toxicity) was on the time (within the Twenties and Nineteen Thirties) with out peer amongst available medicaments. This, nonetheless, additionally offered little incentive to review the scientific use of phages rigorously. As well as, many profitable anecdotal case research have been poorly documented, and it’s thought that many therapy failures have been a consequence of poorly formulated or utilized therapies. Phage remedy’s early challenges to carefully set up itself additionally stemmed from a dearth of well-controlled scientific trials (though with some exceptions; [102,217]) together with the potential for lots of the bacterial infections being handled to spontaneously resolve [6668]; notably, immediately, we have now the same concern as many phage-treated infections are additionally being handled with antibiotics, which, in precept, can result in an infection decision that’s impartial of phage motion [78]. In any case, insufficiencies in scientific rigor seems to have allowed for a development in “skepticism” over the therapeutic potential of phage remedy, a skepticism that result in a Western “abandonment” that lasted for roughly 50 years. See chapter 3 of Kuchment [274] for a narration of those occasions.

Collectively, these points appear to have resulted in long-standing cultural impediments to phage remedy implementation [275]. Skepticism and, finally, Western abandonment of phage remedy should not thought to have been pushed primarily by public notion, nonetheless, however fairly by the actions of physicians or, fairly, by their inaction. Importantly, it’s not as if phage remedy was ever carried out extensively in most international locations even when enthusiasm was strongest, thus permitting for small shifts in what comparatively few physicians have been working towards to drive substantial declines in phage therapeutic use. The identical can’t be stated for the usage of antibiotics, which have been extensively adopted as soon as that they had turn out to be obtainable in adequate portions [276]. The decline in enthusiasm for phage remedy was not the case all over the place, and this, not less than partly, was as a result of the usage of antibiotics was not as nicely carried out all over the place, e.g., within the former Soviet Union [102]. The abandonment of phages by Western drugs was pushed, nonetheless, not simply by the ubiquity of antibiotics but in addition by the truth that broadly focused antibiotics are merely simpler to make use of than narrowly particular phages as antibacterial remedies. As we speak, we are able to additionally add financial impediments as obstacles to broader phage remedy acceptance by Western drugs.


Additional complicating the broader implementation of phage remedy are financial uncertainties related to phage remedy improvement. Whereas biotech corporations usually reach translating fundamental analysis into worthwhile scientific purposes [219], funding into phage remedy nonetheless raises many issues, not least of which is the restricted patentability of phages, together with unmodified enzybiotics [277], as “pure phenomena” or “product[s] of nature” [278]. US patents protecting the usage of pure phages in remedy nonetheless have been granted [279], lots of them claiming that particular phage cocktails are important to scale back the chance of resistance improvement by focused micro organism [280]. Such patents are thought of fragile, nonetheless, and thereby won’t essentially present strong business safety [218]. Genetically engineered phages with enhanced antibacterial exercise against this could also be extra simply protected [221] and thereby may function a safer focus for presidency and personal traders [281283].

Naturally occurring, i.e., not genetically engineered phages, against this are overwhelmingly what have been used within the improvement in addition to scientific implementation of phage therapies. However with out strong patentability, there may be much less monetary incentive to spend money on the form of vigorous analysis vital to beat phage remedy skepticism, notably together with the funding of scientific trials, and likewise towards financing phage remedy business improvement extra broadly. The delicate patentability of naturally occurring phages for phage remedy thus might characterize the best societal problem to phage remedy and, certainly, problem to phage remedy typically in these many international locations the place phages should not but regulatorily authorised as antibacterial remedies. We return to but additional issues of phage remedy financial points within the following, last part of this Essay.

Translating phage remedy to the clinic

“Though extra translational analysis is required earlier than the scientific implementation of phage remedy is possible, phages could also be pivotal in safeguarding the general well being of people within the close to future. [284]

There’s a wealth of preclinical in addition to extra fundamental science-derived knowledge supporting the potential for phage remedy use clinically. On the different excessive, numerous phage remedy facilities and initiatives (Desk 1), corporations, and established analysis teams are actively concerned in creating and testing phage collections and treating folks. Occupying one thing of a center floor are physicians who don’t, on their very own, have entry to phages, or not less than easy accessibility, however who’re capable of hyperlink up with facilities, corporations, or analysis teams to acquire these phages. Initiatives equivalent to Phage Listing facilitate connections between phage suppliers, equivalent to from educational analysis laboratories, with doable phage scientific customers, i.e., docs [285].

General, then, there are 4 common routes to human phage remedy. The primary is administration with out scientific supervision, which is feasible in locations the place phages can be found over-the-counter, notably Georgia and Russia [286]. The second is use by physicians or equal caregivers in areas the place phages have been authorised to be used clinically (e.g., additionally Georgia and Russia). Right here, phage remedy was regulatorily authorised and translated into the clinic many a long time in the past. The necessity for working towards phage therapists to exhibit efficacy in formal and really costly scientific trials, subsequently, is much less urgent. The third method, and one which presently receives essentially the most consideration, is throughout the context of dire want, i.e., involving compassionate use in addition to, usually, customized drugs. This method lends itself much less nicely to offering proof of efficacy as controls are tough to ascertain and mixture of phage remedies with use of standard-of-care antibiotics is common [78]. On this context, phage remedy usually is hunted for the hardest of bacterial an infection circumstances as salvage therapies. This potential for phages to efficiently deal with bacterial infections for which antibiotics have been much less efficient, nonetheless, offers a doable area of interest for each phage remedy use and phage remedy testing.

Lastly are scientific trials, that are essentially restricted in scope and costly to run, however that are important for the express proof of phage security and efficacy that regulators, prescribers, and customers want. To this point, a handful of phage remedy scientific trials have been revealed in English language journals (for English language entry as an alternative to particularly the Russian and Georgian literatures, see [75]). Although fashionable phage remedy scientific trials began out with a lot promise, particularly with the Part I/II trial reported by Wright and colleagues [74], at greatest subsequent trials appear to have met with solely combined outcomes [287,288] and in any other case face many challenges [55], although this may occasionally change as elevated public funding for phage remedy scientific has turn out to be obtainable [144]. Specifically, phages are almost definitely to be examined underneath circumstances the place antibiotics have already been tried as the primary possibility however in any other case could also be discovered to be superior to antibiotic remedies in solely a restricted variety of circumstances. However, there may be nice potential to decide on phages as options to unacceptably poisonous antibiotics [289] or to scale back problematic antibiotic impacts on microbiomes [111,151154].

A last and nontrivial downside is the lowered business enthusiasm to deliver new antibacterial brokers of any variety from the laboratory to the clinic. There’s a common expectation that antibacterial brokers won’t solely be used for under quick intervals of time (i.e., from the purpose of an infection presentation to the purpose of an infection treatment) however might be comparatively cheap throughout that ideally considerably temporary use [290]. Collectively, these financial obstacles characterize important disincentives not simply to phage remedy translation to the clinic but in addition to the introduction of recent antibiotics extra typically. Added to this, however extra particular to phages, is the famous concern of the uncertainty of mental property safety of naturally occurring organic brokers. Nonetheless, to the extent that it could be confirmed in the middle of fashionable scientific trials that phage remedies are capable of treatment bacterial infections when standard remedies have failed and/or that we turn out to be critical as a society, or not less than as subsets of society, to guard our microbiomes, then scientific phage therapies might but rise once more, not simply in just a few choose locales but in addition around the globe. Certainly, as a last phrase, we each counsel and agree that phage remedy may be considered as a 3rd main intervention for treating infectious illnesses after vaccines and antibiotics [250] and are buoyed by phage remedy’s latest scientific successes (Fig 3) and development in use regardless of quite a few present challenges.


  1. 1.
    Krueger AP, Scribner EJ. The bacteriophage: Its nature and its therapeutic use (I). JAMA. 1941;116:2160–2167.
  2. 2.
    Gamaleya NF. Bacteriolysins-ferments destroying micro organism. Russ Arch Pathol Clin Med Bacteriol. 1898;6:607–613.
  3. 3.
    An Bardell D. 1898 report by Gamaleya for a lytic agent particular for Bacillus anthracis. J Hist Med Allied Sci. 1982;37:222–225.
  4. 4.
    Letarov A. The missed bacteriophage: Nikolai F. Gamaleya 1899 paper. Phage (New Rochelle). 2022; 3(2):81–84. pmid:36157283
  5. 5.
    d’Hérelle F. Sur un microbe invisible antagoniste des bacilles dysentériques. C R Acad Sci Ser D. 1917;165:373–375.
  6. 6.
    d’Hérelle F. On an invisible microbe antagonistic to dysentery bacilli. Be aware by M. F. d’Herelle, offered by M. Roux. Comptes Rendus Academiedes Sciences 1917; 165:373–5. Bacteriophage. 2011;1(1):3–5.
  7. 7.
    Twort FW. An investigation on the character of ultra-microscopic viruses. Lancet. 1915;ii(Dec. 4):1241–1243.
  8. 8.
    Twort FW. An investigation on the character of ultra-microscopic viruses. Bacteriophage. 2011;1(3):127–129.
  9. 9.
    Duckworth DH. Who found bacteriophage? Bacteriol Rev. 1976;40:793–802. pmid:795414
  10. 10.
    Hankin ME. L’motion bactéricide des eaux de la Jumna et du Gange sur le vibrion du choléra. Ann Inst Pasteur. 1896;10:511–523.
  11. 11.
    Abedon ST, Thomas-Abedon C, Thomas A, Mazure H. Bacteriophage prehistory: is or just isn’t Hankin, 1896, a phage reference? Bacteriophage. 2011;1(3):174–178. pmid:22164351
  12. 12.
    Sulakvelidze A, Kutter E. Bacteriophage remedy in people. In: Kutter E, Sulakvelidze A, editors. Bacteriophages: Biology and Utility. Boca Raton, Florida: CRC Press; 2005. p. 381–436.
  13. 13.
    Górski A, Międzybrodzki R, Borysowski J. Phage Remedy: A Sensible Method. Cham. Switzerland: Springer Nature Switzerland AG.
  14. 14.
    Harper DR, Abedon ST, Burrowes BH, McConville ML. Bacteriophages: Biology, Expertise, Remedy. Springer Nature Switzerland AG.
  15. 15.
    Bruynoghe R, Maisin J. Essais de thérapeutique au moyen du bactériophage du Staphylocoque. Compt Rend Soc Biol. 1921;85:1120–1121.
  16. 16.
    Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage remedy: from organic mechanisms to future instructions. Cell. 2023; 186(1):17–31. S0092-8674(22)01461-1 [pii]. pmid:36608652
  17. 17.
    Hyman P, Abedon ST. Smaller fleas: viruses of microorganisms. Scientifica. 2012;2012:734023. pmid:24278736
  18. 18.
    Hyman P, Abedon ST. Viruses of Microorganisms. Caister Tutorial Press: Norwich, UK.
  19. 19.
    Abedon ST. Phage-phage, phage-bacteria, and phage-environment communication. In: Witzany G, editors. Biocommunication of Phages. Cham, Switzerland: Springer; 2020. p. 23–70.
  20. 20.
    Turner D, Kropinski AM, Adriaenssens EM. A roadmap for genome-based phage taxonomy. Viruses. 2021;13(3):506. pmid:33803862
  21. 21.
    Lehman SM. Bacteriophage range. In: Hyman P, Abedon ST, editors. Viruses of Microorganisms. Caister Tutorial Press: Norwich, UK; 2018. p. 145–165.
  22. 22.
    Sanz-Gaitero M, Seoane-Blanco M, van Raaij MJ. Construction and performance of bacteriophages. In: Harper DR, Abedon ST, Burrowes B, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 19–91.
  23. 23.
    Abedon ST. Phage evolution and ecology. Adv Appl Microbiol. 2009;67:1–45. pmid:19245935
  24. 24.
    Abedon ST. Measurement does matter—distinguishing bacteriophages by genome size (and ’breadth’). Microbiol Aust. 2011(Might):95–96.
  25. 25.
    Dennehy JJ, Abedon ST. Phage an infection and lysis. In: Harper D, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 341–383.
  26. 26.
    Howard-Varona C, Hargreaves KR, Abedon ST, Sullivan MB. Lysogeny in nature: mechanisms, affect and ecology of temperate phages. ISME J. 2017;11(7):1511–1520. pmid:28291233
  27. 27.
    Łoś J, Zielińka S, Krajewska A, Michalina Z, Małachowska A, Kwaśnicka Okay, et al. Temperate phages, prophages and lysogeny. In: Harper DR, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 119–150.
  28. 28.
    Hobbs Z, Abedon ST. Range of phage an infection varieties and related terminology: the issue with ’lytic or lysogenic’. FEMS Microbiol Lett. 2016; 363(7):fnw047. pmid:26925588
  29. 29.
    Leon M, Bastias R. Virulence discount in bacteriophage resistant micro organism. Entrance Microbiol. 2015;6:343. pmid:25954266
  30. 30.
    Silva JB, Storms Z, Sauvageau D. Host receptors for bacteriophage adsorption. FEMS Microbiol Lett. 2016; 363(4):fnw002. pmid:26755501
  31. 31.
    Dennehy JJ, Abedon ST. Adsorption: phage acquisition of micro organism. In: Harper D, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 93–117.
  32. 32.
    Abedon ST. Bacteriophage adsorption: chance of virion encounter with micro organism and different components affecting charges. Antibiotics (Basel). 2023;12(4):723. pmid:37107086
  33. 33.
    Miller RV, Day M. Contribution of lysogeny, pseudolysogeny, and hunger to phage ecology. In: Abedon ST, editors. Bacteriophage Ecology. Cambridge, UK: Cambridge College Press; 2008. p. 114–143.
  34. 34.
    Bryan D, El-Shibiny A, Hobbs Z, Porter J, Kutter EM. Bacteriophage T4 an infection of stationary section E. coli: life after log from a phage perspective. Entrance Microbiol. 2016;7:1391. pmid:27660625
  35. 35.
    Mäntynen S, Laanto E, Oksanen HM, Poranen MM, Díaz-Muñoz SL. Black field of phage-bacterium interactions: exploring different phage an infection methods. Open Biol. 2021;11(9):210188. pmid:34520699
  36. 36.
    Abedon ST. Evolution of bacteriophage latent interval size. In: Dickins TE, Dickens BJA, editors. Evolutionary Biology: New Views on its Improvement. Cham, Switzerland: Springer; 2023. p. 375–426.
  37. 37.
    Blasdel BG, Abedon ST. Superinfection immunity. Reference Module in Life Sciences. Elsevier; 2017.
  38. 38.
    Mavrich TN, Hatfull GF. Evolution of superinfection immunity in Cluster A mycobacteriophages. MBio. 2019;10(3):e00971–e00919. pmid:31164468
  39. 39.
    Sinha V, Goyal A, Svenningsen SL, Semsey S, Krishna S. In silico evolution of lysis-lysogeny methods reproduces noticed lysogeny propensities in temperate bacteriophages. Entrance Microbiol. 2017;8:1386. pmid:28798729
  40. 40.
    Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford Okay, Harris Okay, et al. Engineered bacteriophages for therapy of a affected person with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–733. pmid:31068712
  41. 41.
    Łoś M, Kuzio J, McConnell MR, Kropinski AM, Wegrzyn G, Christie GE. Lysogenic conversion in micro organism of significance to the meals {industry}. In: Sabour PM, Griffiths MW, editors. Bacteriophages within the Management of Meals- and Waterborne Pathogens. Washington, DC: ASM Press; 2010. p. 157–198.
  42. 42.
    Abedon ST, LeJeune JT. Why bacteriophage encode exotoxins and different virulence components. Evol Bioinform On-line. 2005;1:97–110. pmid:19325857
  43. 43.
    Christie GE, Allison HA, Kuzio J, McShan M, Waldor MK, Kropinski AM. Prophage-induced adjustments in mobile cytochemistry and virulence. In: Hyman P, Abedon ST, editors. Bacteriophages in Well being and Illness. Wallingford, UK: CABI Press; 2012. p. 33–60.
  44. 44.
    Krupovic M, Cvirkaite-Krupovic V, Iranzo J, Prangishvili D, Koonin EV. Viruses of archaea: structural, purposeful, environmental and evolutionary genomics. Virus Res. 2018 244:181–93. S0168-1702(17):30579–8. pmid:29175107
  45. 45.
    Abedon ST, Murray KL. Archaeal viruses, not archaeal phages: an archaeological dig. Archaea. 2013;2013:251245. pmid:23653528
  46. 46.
    Alves DR, Clark J, Abedon ST. Viruses as biocontrol brokers of microorganisms. In: Hyman P, Abedon ST, editors. Viruses of Microorganisms. Caister Tutorial Press: Norwich, UK; 2018. p. 313–330.
  47. 47.
    Gill EE, Brinkman FS. The proportional lack of archaeal pathogens: Do viruses/phages maintain the important thing? Bioessays. 2011;33(4):248–254. pmid:21328413
  48. 48.
    Abedon ST. Are archaeons incapable of being parasites or have we merely failed to note? Bioessays. 2013;35(6):501. pmid:23575903
  49. 49.
    Abedon ST. Why archaea are restricted of their exploitation of different, dwelling organisms. In: Witzany G, editors. Biocommunication of Archaea. 2017. p. 41–66.
  50. 50.
    Hyman P, Atterbury R, Barrow P. Fleas and smaller fleas: virotherapy for parasite infections. Developments Microbiol. 2013;21(5):215–220. S0966-842X(13)00036-X [pii]. pmid:23540830
  51. 51.
    Eager EC. Past phage remedy: virotherapy of protozoal illnesses. Future Microbiol. 2013;8(7):821–823. pmid:23841627
  52. 52.
    Summers WC. The unusual historical past of phage remedy. Bacteriophage. 2012;2(2):130–133. 2012BACTERIOPHAGE011 [pii]. pmid:23050223
  53. 53.
    Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Grey A, et al. International burden of bacterial antimicrobial resistance in 2019: a scientific evaluation. Lancet. 2022;399(10325):629–655. pmid:35065702
  54. 54.
    Abedon ST. Use of phage remedy to deal with long-standing, persistent, or continual bacterial infections. Adv Drug Deliv Rev. 2019;145(Might):18–39. pmid:31708017
  55. 55.
    Gabard J, Jault P. How one can obtain phage remedy scientific trial? In: Górski A, Międzybrodzki R, Borysowski J, editors. Phage Remedy: A Sensible Method. Springer Nature Switzerland AG; 2019. p. 147–168.
  56. 56.
    Petrovic Fabijan A, Lin RCY, Ho J, Maddocks S, Ben Zakour NL, Iredell JR, Westmead Bacteriophage Remedy Group. Security of bacteriophage remedy in extreme Staphylococcus aureus an infection. Nat Microbiol. 2020;5(3):465–472. pmid:32066959
  57. 57.
    Liu D, Van Belleghem JD, de Vries CR, Burgener E, Chen Q, Manasherob R, et al. The protection and toxicity of phage remedy: a evaluation of animal and scientific research. Viruses. 2021;13(7):1268. pmid:34209836
  58. 58.
    Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Security and efficacy of phage remedy in difficult-to-treat infections: a scientific evaluation. Lancet Infect Dis. 2022; 22(8):e208–e220. S1473-3099(21)00612-5 [pii]. pmid:35248167
  59. 59.
    Summers WC. Bacteriophage remedy. Annu Rev Microbiol. 2001;55:437–451. pmid:11544363
  60. 60.
    Summers WC. Historical past of phage analysis and phage remedy. In: Waldor M, Friedman D, Adhya S, editors. Phages: Their Position in Bacterial Pathogenesis and Biotechnology. Washington DC: ASM Press; 2005.
  61. 61.
    Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, et al. Phage remedy in scientific observe: therapy of human infections. Curr Pharm Biotechnol. 2010;11 (1):69–86. pmid:20214609
  62. 62.
    Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage therapy of human infections. Bacteriophage. 2011;1(2):66–85. pmid:22334863
  63. 63.
    Chanishvili N. Phage remedy—historical past from Twort and d’Herelle by way of Soviet expertise to present approaches. Adv Virus Res. 2012 83:3–40. B978-0-12-394438-2.00001–3 [pii]. pmid:22748807
  64. 64.
    Abedon ST. Bacteriophage scientific use as antibactertial “medication”: utility, precedent. Microbiol Spectr. 2017;5(4):BAD-0003-2016.
  65. 65.
    Almeida GMF, Sundberg LR. The forgotten story of Brazilian phage remedy. Lancet Infect Dis. 2020; 20(5):e90–e101. S1473-3099(20)30060-8 [pii]. pmid:32213334
  66. 66.
    Eaton MD, Bayne-Jones S. Bacteriophage remedy: Evaluate of the rules and outcomes of the usage of bacteriophage within the therapy of infections (I). JAMA. 1934;103:1769–1776.
  67. 67.
    Eaton MD, Bayne-Jones S. Bacteriophage remedy: Evaluate of the rules and outcomes of the usage of bacteriophage within the therapy of infections (II). JAMA. 1934;103:1847–1853.
  68. 68.
    Eaton MD, Bayne-Jones S. Bacteriophage remedy: Evaluate of the rules and outcomes of the usage of bacteriophage within the therapy of infections (III). JAMA. 1934;103:1934–1939.
  69. 69.
    Krueger AP, Scribner EJ. The bacteriophage: Its nature and its therapeutic use (II). JAMA. 1941;116:2269–2277.
  70. 70.
    Stent GS. Molecular Biology of Bacterial Viruses. San Francisco, CA: WH Freeman and Co.
  71. 71.
    Ślopek S, Weber-Dąbrowska B, Dąbrowski M, Kucharewicz-Krukowska A. Outcomes of bacteriophage therapy of suppurative bacterial infections within the years 1981–1986. Arch Immunol Ther Exp (Warsz). 1987;35(5):569–583. pmid:3455647
  72. 72.
    Nelson D, Loomis L, Fischetti VA. Prevention and elimination of higher respiratory colonization of mice by group A streptococci through the use of a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A. 2001;98(7):4107–4112. pmid:11259652
  73. 73.
    Hanauer DI, Graham MJ, Betancur L, Bobrownicki A, Cresawn SG, Garlena RA, et al. An inclusive analysis training group (iREC): affect of the SEA-PHAGES program on analysis outcomes and pupil studying. Proc Natl Acad Sci U S A. 2017;114(51):13531–13536. 1718188115 [pii]. pmid:29208718
  74. 74.
    Wright A, Hawkins CH, Anggård EE, Harper DR. A managed scientific trial of a therapeutic bacteriophage preparation in continual otitis as a result of antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349–357.
  75. 75.
    Chanishvili N. A Literature Evaluate of the Sensible Utility of Bacteriophage Analysis. Hauppauge. New York: Nova Publishers.
  76. 76.
    Barnard AML, Fairhead HIM. A commentary on the event of engineered phage as therapeutics. Drug Discov As we speak. 2021; 26(9):2095–8. S1359-6446(21)00286-5 [pii]. pmid:34237459
  77. 77.
    Radetsky P. The great virus. Using bacteriophages to combat antibiotic-resistant bacterial illnesses. Uncover Journal. 1996:50–58.
  78. 78.
    Abedon ST, Danis-Wlodarczyk Okay, Alves DR. Phage remedy within the twenty first Century: is there fashionable, scientific proof of phage-mediated scientific efficacy? Prescribed drugs. 2021;14(11):1157. pmid:34832939
  79. 79.
    Abedon ST. Pathways to phage remedy enlightenment, or why I’ve turn out to be a scientific curmudgeon. Phage (New Rochelle). 2022;3(2):98–111. pmid:36157282
  80. 80.
    Międzybrodzki R, Hoyle N, Zhvaniya F, Łusiak-Szelachowska M, Weber-Dąbrowska B, Łobocka M, et al. Present updates from the long-standing phage analysis facilities in Georgia, Poland, and Russia. In: Harper DR, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 921–951. 1
  81. 81.
    Żaczek M, Gorski A, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Rogóż P, et al. A radical synthesis of phage remedy unit exercise in poland-its historical past, milestones and worldwide recognition. Viruses. 2022;14(6):1170. v14061170 [pii]. pmid:35746642
  82. 82.
    Danis-Wlodarczyk KM, Wozniak DJ, Abedon ST. Treating bacterial infections with bacteriophage-based enzybiotics: in vitro, in vivo and scientific software. Antibiotics (Basel). 2021;10:1497. pmid:34943709
  83. 83.
    Heselpoth RD, Swift SM, Linden SB, Mitchell MS, Nelson DC. Enzybiotics: endolysins and bacteriocins. In: Harper DR, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. Springer Worldwide Publishing AG; 2021. p. 989–1030. 4
  84. 84.
    Hermoso JA, Garcia JL, Garcia P. Taking goal on bacterial pathogens: from phage remedy to enzybiotics. Curr Opin Mirobiol. 2007;10(5):461–472. pmid:17904412
  85. 85.
    Rodriguez-Rubio L, Martinez B, Donovan DM, Rodriguez A, Garcia P. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit Rev Microbiol. 2013;39(4):427–434. pmid:22991936
  86. 86.
    Dams D, Briers Y. Enzybiotics: enzyme-based antibacterials as therapeutics. Adv Exp Med Biol. 2019;1148:233–253. pmid:31482502
  87. 87.
    Kutter E. Phage remedy: bacteriophages as pure, self-limiting antibiotics. In: Pizzorno W, editors. Textbook of Pure Medication, third ed. Churchill Livingston; 2005. p. 1147–1161.
  88. 88.
    Häusler T. Viruses vs. Superbugs: A Answer to the Antibiotics Disaster. New York, NY: Macmillan.
  89. 89.
    Loc-Carrillo C, Abedon ST. Execs and cons of phage remedy. Bacteriophage. 2011;1(2):111–114. pmid:22334867
  90. 90.
    Curtright AJ, Abedon ST. Phage remedy: emergent property pharmacology. J Bioanalyt Biomed. 2011;S3:010.
  91. 91.
    McCallin S, Sacher JC, Zheng J, Chan BK. Present state of compassionate phage remedy. Viruses. 2019;11(4):343. v11040343 [pii]. pmid:31013833
  92. 92.
    Dąbrowska Okay, Górski A, Abedon ST. Bacteriophage pharmacology and immunology. In: Harper D, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 295–339.
  93. 93.
    Stacey HJ, De SS, Jones JD. The protection and efficacy of phage remedy: a scientific evaluation of scientific and security trials. Antibiotics (Basel). 2022;11(10):1340. antibiotics11101340 [pii]; antibiotics-11-01340 [pii]. pmid:36289998
  94. 94.
    Kortright KE, Doss-Gollin S, Chan BK, Turner PE. Evolution of bacterial cross-resistance to lytic phages and albicidin antibiotic. Entrance Microbiol. 2021;12:658374. pmid:34220747
  95. 95.
    McCallin S, Menzi C, Lassen S, Daraspe J, Oechslin F, Moreillon P. Antibiotic publicity results in lowered phage susceptibility in vancomycin intermediate Staphylococcus aureus (VISA). Antimicrob Brokers Chemother. 2022;66(7):e0224721. pmid:35708333
  96. 96.
    Rosas NC, Lithgow T. Focusing on bacterial outer-membrane remodelling to affect antimicrobial drug resistance. Developments Microbiol. 2022; 30(6):544–52. S0966-842X(21)00268-7 [pii]. pmid:34872824
  97. 97.
    Sacher JC, Zheng J, McCallin S. Sourcing phages for compassionate use. Microbiol Aust. 2019;40(1):24–27.
  98. 98.
    Sacher JC, Zheng J. Phage remedy collaboration and compassionate use. In: Harper DR, Abedon ST, Burrowes BH, McConville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 1069–1098.
  99. 99.
    Nameless. The unregulated potential of phages. The Lancet. Microbe. 2023;4(3):e126. pmid:36868251
  100. 100.
    Gilbey T, Ho J, Cooley LA, Petrovic FA, Iredell JR. Adjunctive bacteriophage remedy for prosthetic valve endocarditis as a result of Staphylococcus aureus. Med J Aust. 2019;211(3):142–143. pmid:31281964
  101. 101.
    Fabijan AP, Ben Zakour NL, Ho J, Lin RCY, Iredell J. Polyclonal Staphylococcus aureus bacteremia. Ann Intern Med. 2019; 171(12):940–1. 2751455 [pii]. pmid:31525739
  102. 102.
    Marongiu L, Burkard M, Lauer UM, Hoelzle LE, Venturelli S. Reassessment of historic scientific trials helps the effectiveness of phage remedy. Clin Microbiol Rev. 2022;34(4):e0006222. pmid:36069758
  103. 103.
    Hatfull GF, Dedrick RM, Schooley RT. Phage remedy for antibiotic-resistant bacterial infections. Annu Rev Med. 2022;73:197–211. pmid:34428079
  104. 104.
    Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Compassionate use of bacteriophage remedy for foot ulcer therapy as an efficient step for shifting towards scientific trials. Strategies Mol Biol. 2018;1693:159–170. pmid:29119440
  105. 105.
    Morozova VV, Kozlova YN, Ganichev DA, Tikunova NV. Bacteriophage therapy of contaminated diabetic foot ulcers. Strategies Mol Biol. 2018;1693:151–158. pmid:29119439
  106. 106.
    Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage therapy of an aortic graft contaminated with Pseudomonas aeruginosa. Evol Med Pub Well being. 2018;1(1):60–66. pmid:29588855
  107. 107.
    Hoyle N, Zhvaniya P, Balarjishvili N, Bolkvadze D, Nadareishvili L, Nizharadze D, et al. Phage remedy towards Achromobacter xylosoxidans lung an infection in a affected person with cystic fibrosis: a case report. Res Microbiol. 2018;169(9):540–542. pmid:29777836
  108. 108.
    Ooi ML, Drilling AJ, Morales S, Fong S, Moraitis S, Macias-Valle L, et al. Security and tolerability of bacteriophage remedy for continual rhinosinusitis as a result of Staphylococcus aureus. JAMA. Otolaryngol Head Neck Surg. 2019;145 (8):723–729. 2735735 [pii]. pmid:31219531
  109. 109.
    Aslam S, Courtwright AM, Koval C, Lehman SM, Morales S, Furr C-LL, et al. Early scientific expertise of bacteriophage remedy in three lung transplant recipients. Am J Transplant. 2019;19(9):2631–2639. pmid:31207123
  110. 110.
    Duplessis CA, Stockelman M, Hamilton T, Merril G, Brownstein M, Bishop-Lilly Okay, et al. A case collection of emergency investigational new drug purposes for bacteriophages treating recalcitrant multi-drug resistant bacterial infections: confirmed security and a sign of efficacy. J Intens Crit Care. 2019;5(2):11.
  111. 111.
    Febvre HP, Rao S, Gindin M, Goodwin NDM, Finer E, Vivanco JS, et al. PHAGE examine: results of supplemental bacteriophage consumption on irritation and intestine microbiota in wholesome adults. Vitamins. 2019;11(3):666. nu11030666 [pii]. pmid:30897686
  112. 112.
    Kuipers S, Ruth MM, Mientjes M, de Sevaux RGL, van Ingen J. A Dutch case report of profitable therapy of continual relapsing urinary tract an infection with bacteriophages in a renal transplant affected person. Antimicrob Brokers Chemother. 2019;64(1):e01281–e01219. AAC.01281-19 [pii]. pmid:31611357
  113. 113.
    Maddocks S, Petrovic Fabijan A, Ho J, Lin RCY, Ben Zakour NL, Dugan C, et al. Bacteriophage remedy of ventilator-associated pneumonia and empyema brought on by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019;200(9):1179–1181. pmid:31437402
  114. 114.
    Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, et al. Profitable therapy of antibiotic resistant poly-microbial bone an infection with bacteriophages and antibiotics mixture. Clin Infect Dis. 2019;69(11):2015–2018. 5380636 [pii]. pmid:30869755
  115. 115.
    Rubalskii E, Ruemke S, Salmoukas C, Boyle EC, Warnecke G, Tudorache I, et al. Bacteriophage remedy for vital infections associated to cardiothoracic surgical procedure. Antibiotics (Basel). 2020;9(5):232. antibiotics9050232 [pii]. pmid:32380707
  116. 116.
    Corbellino M, Kieffer N, Kutateladze M, Balarjishvili N, Leshkasheli L, Askilashvili L, et al. Eradication of a multidrug-resistant, carbapenemase-producing Klebsiella pneumoniae isolate following oral and intra-rectal remedy with a customized made, lytic bacteriophage preparation. Clin Infect Dis. 2020;70(9):1998–2001. 5550234 [pii]. pmid:31414123
  117. 117.
    Wu N, Dai J, Guo M, Li J, Zhou X, Li F, et al. Pre-optimized phage remedy on secondary Acinetobacter baumannii an infection in 4 vital COVID-19 sufferers. Emerg Microbes Infect. 2021;10(1):612–618. pmid:33703996
  118. 118.
    Cano EJ, Caflisch KM, Bollyky PL, Van Belleghem JD, Patel R, Fackler J, et al. Phage remedy for limb-threatening prosthetic knee Klebsiella pneumoniae an infection: case report and in vitro characterization of anti-biofilm exercise. Clin Infect Dis. 2021;73(1):e144–e151. 5874921 [pii]. pmid:32699879
  119. 119.
    Johri AV, Johri P, Hoyle N, Pipia L, Nadareishvili L, et al. Case report: Persistent bacterial prostatitis handled with phage remedy after a number of failed antibiotic remedies. Entrance Pharmacol. 2021;12:692614. 692614 [pii]. pmid:34177601
  120. 120.
    Khatami A, Lin RCY, Petrovic-Fabijan A, Alkalay-Oren S, Almuzam S, Britton PN, et al. Bacterial lysis, autophagy and innate immune responses throughout adjunctive phage remedy in a toddler. EMBO Mol Med. 2021;13(9):e13936. pmid:34369652
  121. 121.
    Federici S, Kredo-Russo S, Valdes-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, et al. Focused suppression of human IBD-associated intestine microbiota commensals by phage consortia for therapy of intestinal irritation. Cell. 2022; 185(16):2879–98. S0092-8674(22)00850-9 [pii]. pmid:35931020
  122. 122.
    Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, et al. Phage remedy of Mycobacterium Infections: compassionate-use of phages in twenty sufferers with drug-resistant mycobacterial illness. Clin Infect Dis. 2023;76(1):103–112. 6604409 [pii]. pmid:35676823
  123. 123.
    Little JS, Dedrick RM, Freeman KG, Cristinziano M, Smith BE, Benson CA, et al. Bacteriophage therapy of disseminated cutaneous Mycobacterium chelonae an infection. Nat Commun. 2022;13(1):2313. pmid:35504908
  124. 124.
    Nick JA, Dedrick RM, Grey AL, Vladar EK, Smith BE, Freeman KG, et al. Host and pathogen response to bacteriophage engineered towards Mycobacterium abscessus lung an infection. Cell. 2022; 185(11):1860–74. S0092-8674(22)00471-8 [pii]. pmid:35568033
  125. 125.
    Pirnay JP. Phage remedy within the 12 months 2035. Entrance Microbiol. 2020;11:1171. pmid:32582107
  126. 126.
    Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De VD, Ameloot C, et al. The magistral phage. Viruses. 2018;10(2):852. v10020064 [pii]. pmid:29415431
  127. 127.
    Ackermann H-W. Phage or Phages. Bacteriophage. 2011;1(1):52–53. 2159-7073-1-1-9 [pii]. pmid:21687536
  128. 128.
    Onsea J, Uyttebroek S, Chen B, Wagemans J, Lood C, Van Gerven L, et al. Bacteriophage remedy for difficult-to-treat infections: the implementation of a multidisciplinary phage activity power (The PHAGEFORCE Examine Protocol). Viruses. 2021;13(8). v13081543 [pii]. pmid:34452408
  129. 129.
    Khatami A, Foley DA, Warner MS, Barnes EH, Peleg AY, Li J, et al. Standardised therapy and monitoring protocol to evaluate security and tolerability of bacteriophage remedy for grownup and paediatric sufferers (STAMP examine): protocol for an open-label, single-arm trial. BMJ Open. 2022;12(12):e065401. pmid:36600337
  130. 130.
    Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, et al. Issues for the usage of phage remedy in scientific observe. Antimicrob Brokers Chemother. 2022;66(3):AAC0207121. pmid:35041506
  131. 131.
    Goodridge LD. Designing phage therapeutics. Curr Pharm Biotechnol. 2010;11(1):15–27. pmid:20214605
  132. 132.
    Kiro R, Shitrit D, Qimron U. Environment friendly engineering of a bacteriophage genome utilizing the kind I-E CRISPR-Cas system. RNA Biol. 2014 11(1):42–4. 27766 [pii]. 2013RNABIOL0294R [pii]. pmid:24457913
  133. 133.
    Gibb B, Hyman P, Schneider CL. The various purposes of engineered bacteriophages—an outline. Prescribed drugs 2021;14(7):634. ph14070634 [pii]. pmid:34208847
  134. 134.
    Yehl Okay, Lemire S, Yang AC, Ando H, Mimee M, Torres MT, et al. Engineering phage host-range and suppressing bacterial resistance by way of phage tail fiber mutagenesis. Cell. 2019;179(2):459–69. S0092-8674(19)31022-0 [pii]. pmid:31585083
  135. 135.
    Yoichi M, Abe M, Miyanaga Okay, Unno H, Tanji Y. Alteration of tail fiber protein gp38 permits T2 phage to contaminate Escherichia coli O157:H7. J Biotechnol. 2005;115(1):101–107. pmid:15607229
  136. 136.
    Mahichi F, Synnott AJ, Yamamichi Okay, Osada T, Tanji Y. Web site-specific recombination of T2 phage utilizing IP008 lengthy tail fiber genes offers a focused technique for increasing host vary whereas retaining lytic exercise. FEMS Microbiol Lett. 2009;295(2):211–217. pmid:19453513
  137. 137.
    Zhang H, Fouts DE, Depew J, Stevens RH. Genetic modifications to temperate Enterococcus faecalis phage Ef11 that abolish the institution of lysogeny and sensitivity to repressor, and improve host vary and productiveness of lytic an infection. Microbiology. 2013;159(Pt 6):1023–1035. 067116 [pii].
  138. 138.
    Łobocka M, Dąbrowska Okay, Górski A. Engineered bacteriophage therapeutics: rationale, challenges and future. BioDrugs. 2021;35(3):255–280. pmid:33881767
  139. 139.
    Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, et al. Lengthy-circulating bacteriophage as antibacterial brokers. Proc Natl Acad Sci U S A. 1996;93(8):3188–3192. pmid:8622911
  140. 140.
    Vitiello CL, Merril CR, Adhya S. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system greater than a 1000-fold. Virus Res. 2005;114(1–2):101–103. pmid:16055223
  141. 141.
    Pei R, Lamas-Samanamud GR. Inhibition of biofilm formation by T7 bacteriophages producing quorum quenching enzymes. Appl Environ Microbiol. 2014;80(17):5340–5348. AEM.01434-14 [pii]. pmid:24951790
  142. 142.
    Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A. 2007;104(27):11197–11202. pmid:17592147
  143. 143.
    Marinelli LJ, Piuri M, Swigoňová Z, Balachandran A, Oldfield LM, van Kessel JC, et al. BRED: a easy and highly effective software for establishing mutant and recombinant bacteriophage genomes. PLoS ONE. 2008;3(12):e3957. pmid:19088849
  144. 144.
    Cahan E. As superbugs flourish, bacteriophage remedy recaptures researchers’ curiosity. JAMA. 2023;329(10):781–784. 2801953 [pii]. pmid:36811929
  145. 145.
    Kutter EM, Kuhl SJ, Abedon ST. Re-establishing a spot for phage remedy in western drugs. Future Microbiol. 2015;10:685–688. pmid:26000644
  146. 146.
    Merabishvili M, Pirnay JP, Vogele Okay, Malik DJ. Manufacturing of phage therapeutics and formulations: revolutionary approaches. In: Górski A, Międzybrodzki R, Borysowski J, editors. Phage Remedy: A Sensible Method. Springer Nature Switzerland AG; 2019. p. 3–41.
  147. 147.
    Pirnay JP, Ferry T, Resch G. Latest progress towards the implementation of phage remedy in Western drugs. FEMS Microbiol Rev. 2022;46(1):fuab040. 6325169 [pii]. pmid:34289033
  148. 148.
    Dąbrowska Okay, Abedon ST. Pharmacologically conscious phage remedy: pharmacodynamic and pharmacokinetic obstacles to phage antibacterial motion in animal and human our bodies. Microbiol Mol Biol Rev. 2019 83(4):e00012–e00019. pmid:31666296
  149. 149.
    Hyman P, Abedon ST. Bacteriophage host vary and bacterial resistance. Adv Appl Microbiol. 2010;70:217–248. pmid:20359459
  150. 150.
    Gencay YE, Gambino M, From PT, Brondsted L. The genera of bacteriophages and their receptors are the most important determinants of host vary. Environ Microbiol. 2019;21(6):2095–2111. pmid:30888719
  151. 151.
    Nale JY, Redgwell TA, Millard A, Clokie MRJ. Efficacy of an optimised bacteriophage cocktail to clear Clostridium difficile in a batch fermentation mannequin. Antibiotics (Basel). 2018;7(1):13. pmid:29438355
  152. 152.
    Cepko LCS, Garling EE, Dinsdale MJ, Scott WP, Bandy L, Good T, et al. Myoviridae phage PDX kills enteroaggregative Escherichia coli with out human microbiome dysbiosis. J Med Microbiol. 2020;69(2):309–323. pmid:32011231
  153. 153.
    Galtier M, De Sordi L, Maura D, Arachchi H, Volant S, Dillies MA, et al. Bacteriophages to scale back intestine carriage of antibiotic resistant uropathogens with low affect on microbiota composition. Environ Microbiol. 2016;18(7):2237–2245. pmid:26971586
  154. 154.
    Hsu BB, Gibson TE, Yeliseyev V, Liu Q, Lyon L, Bry L, et al. Dynamic modulation of the intestine microbiota and metabolome by bacteriophages in a mouse mannequin. Cell Host Microbe. 2019;25(6):803–814. S1931-3128(19)30246-X [pii]. pmid:31175044
  155. 155.
    Abedon ST, Danis-Wlodarczyk KM, Wozniak DJ. Phage cocktail improvement for bacteriophage remedy: towards enhancing spectrum of exercise breadth and depth. Prescribed drugs. 2021;14(10):1019. pmid:34681243
  156. 156.
    Bono LM, Mao S, Accomplished RE, Okamoto KW, Chan BK, Turner PE. Advancing phage remedy by way of the lens of virus host-breadth and emergence potential. Adv Virus Res. 2021 111:63–110. S0065-3527(21)00032-4 [pii]. pmid:34663499
  157. 157.
    Lood C, Haas PJ, van Noort V, Lavigne R. Purchasing for phages? Unpacking design guidelines for therapeutic phage cocktails. Curr Opin Virol. 2022;52:236–43. S1879-6257(21)00168-1 [pii]. pmid:34971929
  158. 158.
    Kutateladze M, Adamia R. Phage remedy expertise on the Eliava Institute. Med Mal Infect. 2008;38(8):426–430. pmid:18687542
  159. 159.
    McCallin S, Alam SS, Barretto C, Sultana S, Berger B, Huq S, et al. Security evaluation of a Russian phage cocktail: from metaGenomic evaluation to oral software in wholesome human topics. Virology. 2013;443(2):187–96. S0042-6822(13)00302-4 [pii]. pmid:23755967
  160. 160.
    Zaldastanishvili E, Leshkasheli L, Dadiani M, Nadareishvili L, Askilashvili L, Kvatadze N, et al. Phage remedy expertise on the Eliava Phage Remedy Middle: three circumstances of bacterial persistence. Viruses. 2021;13(10):1901. pmid:34696331
  161. 161.
    Burrowes BH, Molineux IJ, Fralick JA. Directed in vitro evolution of therapeutic bacteriophages: the Appelmans protocol. Viruses. 2019;11(3):241. pmid:30862096
  162. 162.
    Rohde C, Resch G, Pirnay JP, Blasdel BG, Debarbieux L, Gelman D, et al. Knowledgeable opinion on three phage remedy associated subjects: bacterial phage resistance, phage coaching and prophages in bacterial manufacturing strains. Viruses. 2018;10(4):178. pmid:29621199
  163. 163.
    Cervera C. Present panorama on phage remedy in infections: time to go away it behind for good? Clin Microbiol Infect. 2023. S1198-743X(23)00043-5 [pii]. pmid:36736660
  164. 164.
    Koonin EV, Makarova KS, Wolf YI, Krupovic M. Evolutionary entanglement of cell genetic components and host defence techniques: weapons for rent. Nat Rev Genet. 2020;21(2):119–131. pmid:31611667
  165. 165.
    Hussain FA, Dubert J, Elsherbini J, Murphy M, VanInsberghe D, Arevalo P, et al. Fast evolutionary turnover of cell genetic components drives bacterial resistance to phages. Science. 2021;374(6566):488–492. pmid:34672730
  166. 166.
    Kortright KE, Chan BK, Turner PE. Excessive-throughput discovery of phage receptors utilizing transposon insertion sequencing of micro organism. Proc Natl Acad Sci U S A. 2020;117(31):18670–18679. pmid:32675236
  167. 167.
    Abedon ST. Ecology and evolutionary biology of hindering phage remedy: the phage tolerance vs. phage resistance of bacterial biofilms. Antibiotics (Basel). 2023;11(2):245. pmid:36830158
  168. 168.
    Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, et al. Synergy between the host immune system and bacteriophage is important for profitable phage remedy towards an acute respiratory pathogen. Cell Host Microbe. 2017;22(1):38–47. S1931-3128(17)30258-5 [pii]. pmid:28704651
  169. 169.
    Burmeister AR, Fortier A, Roush C, Lessing AJ, Bender RG, Barahman R, et al. Pleiotropy complicates a trade-off between phage resistance and antibiotic resistance. Proc Natl Acad Sci U S A. 2020;117(21):11207–11216. pmid:32424102
  170. 170.
    Gordillo Altamirano F, Forsyth JH, Patwa R, Kostoulias X, Trim M, Subedi D, et al. Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nat Microbiol. 2021;6(2):157–161. pmid:33432151
  171. 171.
    Wang X, Loh B, Gordillo Altamirano F, Yu Y, Hua X, Leptihn S. Colistin-phage mixtures lower antibiotic resistance in Acinetobacter baumannii by way of adjustments in envelope structure. Emerg Microbes Infect. 2021;10(1):2205–2219. pmid:34736365
  172. 172.
    Abedon ST. Bacteriophages as Drivers of Evolution: An Evolutionary Ecological Perspective. Cham, Switzerland: Springer.
  173. 173.
    Torres-Barceló C, Turner PE, Buckling A. Mitigation of advanced bacterial resistance to phage remedy. Curr Opin Virol. 2022;53:101201. S1879-6257(22)00008-6 [pii]. pmid:35180532
  174. 174.
    Leekha S, Terrell CL, Edson RS. Basic rules of antimicrobial remedy. Mayo Clin Proc. 2011;86(2):156–67. S0025-6196(11)60140-7 [pii]. pmid:21282489
  175. 175.
    Abedon ST. Phage-antibiotic mixture remedies: antagonistic impacts of antibiotics on the pharmacodynamics of phage remedy? Antibiotics (Basel). 2019;8(4):182. pmid:31614449
  176. 176.
    Danis-Wlodarczyk KM, Cai A, Chen A, Gittrich MR, Sullivan MB, Wozniak DJ, et al. Pals or foes? Fast willpower of dissimilar colistin and ciprofloxacin antagonism of Pseudomonas aeruginosa phages. Prescribed drugs. 2021;14(11):1162. pmid:34832944
  177. 177.
    Zuo P, Yu P, Alvarez PJJ. Aminoglycosides antagonize bacteriophage proliferation, attenuating phage suppression of bacterial development, biofilm formation, and antibiotic resistance. Appl Environ Microbiol. 2021;87(15):e0046821. pmid:34020940
  178. 178.
    Kever L, Hardy A, Luthe T, Hunnefeld M, Gatgens C, Milke L, et al. Aminoglycoside antibiotics inhibit phage an infection by blocking an early step of the an infection cycle. MBio. 2022;13(3):e0078322. pmid:35506667
  179. 179.
    Łusiak-Szelachowska M, Międzybrodzki R, Drulis-Kawa Z, Cater Okay, Knezevic P, Winogradow C, et al. Bacteriophages and antibiotic interactions in scientific observe: what we have now realized to date. J Biomed Sci. 2022;29(1):23. pmid:35354477
  180. 180.
    Abedon ST. Additional issues on tips on how to enhance phage remedy experimentation, observe, and reporting: pharmacodynamics views. Phage (New Rochelle). 2022;3(2):95–97. pmid:36148139
  181. 181.
    Chaudhry WN, Concepcion-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR. Synergy and order results of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE. 2017;12(1):e0168615. pmid:28076361
  182. 182.
    Morrisette T, Kebriaei R, Lev KL, Morales S, Rybak MJ. Bacteriophage therapeutics: a primer for clinicians on phage-antibiotic mixtures. Pharmacotherapy. 2020;40(2):153–168. pmid:31872889
  183. 183.
    Li X, He Y, Wang Z, Wei J, Hu T, Si J, et al. A mix remedy of phages and antibiotics: two is healthier than one. Int J Biol Sci. 2021;17(13):3573–3582. pmid:34512166
  184. 184.
    Torres-Barceló C, Hochberg ME. Evolutionary rationale for phages as enhances of antibiotics. Developments Microbiol. 2016;24(4):249–56. S0966-842X(15)00302-9 [pii]. pmid:26786863
  185. 185.
    Kebriaei R, Lev Okay, Morrisette T, Stamper KC, Abdul-Mutakabbir JC, Lehman SM, et al. Bacteriophage-antibiotic mixture technique: an aternative towards methicillin-resistant phenotypes of Staphylococcus aureus. Antimicrob Brokers Chemother. 2020;64 (7). pmid:32393490
  186. 186.
    Bonhoeffer S, Lipsitch M, Levin BR. Evaluating therapy protocols to forestall resistance. Proc Natl Acad Sci U S A. 1997;94(22):12106–12111.
  187. 187.
    Fischbach MA. Mixture therapies for combating antimicrobial resistance. Curr Opin Microbiol. 2011;14(5):519–23. S1369-5274(11)00137-8 [pii]. pmid:21900036
  188. 188.
    REX Consortium. Heterogeneity of choice and the evolution of resistance. Developments Ecol Evol. 2013;28(2):110–118. pmid:23040463
  189. 189.
    Cadinanos J, Montejano R, de Miguel BR, Marcelo C, Arribas JR. Dangers and advantages of lowering the variety of medication to deal with HIV-1 an infection. Knowledgeable Opin Drug Saf. 2021;20(4):397–409. pmid:33557651
  190. 190.
    Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage choice restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016 6:26717. pmid:27225966
  191. 191.
    Coyne AJK, Stamper Okay, Kebriaei R, Holger DJ, El Ghali A, Morrisette T, et al. Phage cocktails with daptomycin and ampicillin eradicates biofilm-embedded multidrug-resistant Enterococcus faecium with preserved phage susceptibility. Antibiotics (Basel). 2022;11(9):1175. pmid:36139953
  192. 192.
    Schneider CL. Bacteriophage-mediated horizontal gene switch: transduction. In: Harper DR, Abedon ST, Burrowes B, Mcconville M, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 151–192.
  193. 193.
    Ammann A, Neve H, Geis A, Heller KJ. Plasmid switch by way of transduction from Streptococcus thermophilus to Lactococcus lactis. J Bacteriol. 2008;190(8):3083–3087.
  194. 194.
    Casas V, Maloy S. The function of phage within the adaptation of micro organism to new environmental niches. In: Rampelotto PH, editors. Molecular Mechanisms of Microbial Evolution. Springer; 2018. p. 267–306.
  195. 195.
    Chiang YN, Penades JR, Chen J. Genetic transduction by phages and chromosomal islands: the brand new and noncanonical. PLoS Pathog. 2019;15 (8):e1007878. pmid:31393945
  196. 196.
    Humphrey S, San MA, Toll-Riera M, Connolly J, Flor-Duro A, Chen J, et al. Staphylococcal phages and pathogenicity islands drive plasmid evolution. Nat Commun. 2021;12(1):5845. pmid:34615859
  197. 197.
    Harrison E, Brockhurst MA. Ecological and evolutionary advantages of temperate phage: what does or doesn’t kill you makes you stronger. Bioessays. 2017;39(12). pmid:28983932
  198. 198.
    Abedon ST. Transduction of enormous quantities of DNA. In: Bacteriophages as Drivers of Evolution: An Evolutionary Ecological Perspective. Cham, Switzerland: Springer; 2022. p. 137–150.
  199. 199.
    Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage remedy. Biotechnol Lett. 2007;29(7):995–1003. pmid:17364214
  200. 200.
    Thiel Okay. Outdated dogma, new tips—twenty first Century phage remedy. Nat Biotechnol. 2004;22(1):31–36. pmid:14704699
  201. 201.
    Górski A, Międzybrodzki R, Borysowski J, Dąbrowska Okay, Wierzbicki P, Ohams M, et al. Phage as a modulator of immune responses: sensible implications for phage remedy. Adv Virus Res. 2012 83:41–71. pmid:22748808
  202. 202.
    Dąbrowska Okay, Miernikiewicz P, Piotrowicz A, Hodyra Okay, Owczarek B, Lecion D, et al. Immunogenicity research of proteins forming the T4 phage head floor. J Virol. 2014;88(21):12551–12557. pmid:25142581
  203. 203.
    Weber-Dąbrowska B, Zimecki M, Mulczyk M, Górski A. Impact of phage remedy on the turnover and performance of peripheral neutrophils. FEMS Immunol Med Microbiol. 2002;34(2):135–138. pmid:12381464
  204. 204.
    Przerwa A, Zimecki M, Switala-Jelen Okay, Dąbrowska Okay, Krawczyk E, Luczak M, et al. Results of bacteriophages on free radical manufacturing and phagocytic features. Med Microbiol Immunol. 2006;195:143–150. pmid:16447074
  205. 205.
    Górski A, Weber-Dąbrowska B. The potential function of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci. 2005;62(5):511–519. pmid:15747058
  206. 206.
    d’Hérelle F, Smith GH. The Bacteriophage: Its Position in Immunity. Baltimore: Williams and Wilkins Co./Waverly Press.
  207. 207.
    Krut O, Bekeredjian-Ding I. Contribution of the immune response to phage remedy. J Immunol 2018;200(9):3037–3044. pmid:29685950
  208. 208.
    Barr JJ, Auro R, Furlan M, Whiteson KL, Erb ML, Pogliano J, et al. Bacteriophage adhering to mucus present a non-host-derived immunity. Proc Natl Acad Sci U S A. 2013;110(26):10771–10776. pmid:23690590
  209. 209.
    Zhang T, Breitbart M, Lee WH, Run J-Q, Wei CL, Soh SWL, et al. RNA viral group in human feces: prevalence of plant pathogenic viruses. PLoS Biol. 2006;4:e3. pmid:16336043
  210. 210.
    Khan Mirzaei M, Maurice CF. Mènage à trois within the human intestine: interactions between host, micro organism and phages. Nat Rev Microbiol. 2017;15(7):397–408. pmid:28461690
  211. 211.
    Żaczek M, Łusiak-Szelachowska M, Jonczyk-Matysiak E, Weber-Dąbrowska B, Międzybrodzki R, Owczarek B, et al. Antibody manufacturing in response to staphylococcal MS-1 phage cocktail in sufferers present process phage remedy. Entrance Microbiol. 2016;7:1681. pmid:27822205
  212. 212.
    Jerne NK. The presence in regular serum of particular antibody towards bacteriophage T4 and its improve throughout the earliest phases of immunization. J Immunol. 1956;76:209–216. pmid:13306956
  213. 213.
    Łusiak-Szelachowska M, Żaczek M, Weber-Dąbrowska B, Międzybrodzki R, Klak M, Fortuna W, et al. Phage neutralization by sera of sufferers receiving phage remedy. Viral Immunol. 2014;27(6):295–304. pmid:24893003
  214. 214.
    Hodyra-Stefaniak Okay, Miernikiewicz P, Drapala J, Drab M, Jonczyk-Matysiak E, Lecion D, et al. Mammalian host-versus-phage immune response determines phage destiny in vivo. Sci Rep. 2015;5:14802. pmid:26440922
  215. 215.
    Dufour N, Delattre R, Ricard JD, Debarbieux L. The lysis of pathogenic Escherichia coli by bacteriophages releases much less endotoxin than β-lactams. Clin Infect Dis. 2017;64(11):1582–1588. 3058815 [pii]. pmid:28329379
  216. 216.
    Parfitt T. Georgia: an unlikely stronghold for bacteriophage remedy. Lancet. 2005;365(9478):2166–2167. pmid:15986542
  217. 217.
    Myelnikov D. An alternate treatment: the adoption and survival of bacteriophage remedy within the USSR, 1922–1955. J Hist Med Allied Sci. 2018;73 (4):385–411. 5128730 [pii]. pmid:30312428
  218. 218.
    Henein A. What are the restrictions on the broader therapeutic use of phage? Bacteriophage. 2013;3(2):e24872.2012BACTERIOPHAGE0028R [pii]. pmid:24228220
  219. 219.
    Anomaly J. The way forward for phage: moral challenges of utilizing phage remedy to deal with bacterial infections. Public Well being Ethics. 2020;13(1):82–88. pmid:32760449
  220. 220.
    Furfaro LL, Payne MS, Chang BJ. Bacteriophage remedy: scientific trials and regulatory hurdles. Entrance Cell Infect Microbiol. 2018;8:376. pmid:30406049
  221. 221.
    Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J. Present challenges and future alternatives of phage remedy. FEMS Microbiol Rev. 2020;44(6):684–700. 5849005 [pii]. pmid:32472938
  222. 222.
    Fauconnier A. Phage remedy regulation: from evening to daybreak. Viruses. 2019;11(4):352. pmid:30999559
  223. 223.
    Verbeken G, Pirnay JP. European regulatory features of phage remedy: magistral phage preparations. Curr Opin Virol. 2022 52:24–9. S1879-6257(21)00139-5 [pii]. pmid:34801778
  224. 224.
    Abedon ST, Thomas-Abedon C. Phage remedy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28–47. pmid:20214606
  225. 225.
    Danis-Wlodarczyk Okay, Dąbrowska Okay, Abedon ST. Phage remedy: the pharmacology of antibacterial viruses. Curr Points Mol Biol. 2021;40:81–164. pmid:32503951
  226. 226.
    Dąbrowska Okay. Phage remedy: what components form phage pharmacokinetics and bioavailability? Systematic and demanding evaluation. Med Res Rev. 2019;39(5):2000–2025. pmid:30887551
  227. 227.
    Vipra A, Desai SN, Junjappa RP, Roy P, Poonacha N, Ravinder P, et al. Figuring out the minimal inhibitory focus of bacteriophages: potential benefits. Adv Microbiol. 2013;3(2):181–190.
  228. 228.
    Liu GC, Inexperienced SI, Min L, Clark JR, Salazar KC, Terwilliger AL, et al. Phage-antibiotic synergy is pushed by a novel mixture of antibacterial mechanism of motion and stoichiometry. MBio. 2020;11(4):e01462–e01420. pmid:32753497
  229. 229.
    Aghaee BL, Khan MM, Alikhani MY, Mojtahedi A, Maurice CF. Bettering the inhibitory impact of phages towards Pseudomonas aeruginosa remoted from a burn affected person utilizing a mix of phages and antibiotics. Viruses. 2021;13(2). pmid:33670028
  230. 230.
    Kortright KE, Chan BK, Koff JL, Turner PE. Phage remedy: a renewed method to fight antibiotic-resistant micro organism. Cell Host Microbe. 2019;25(2):219–32. S1931-3128(19)30052-6 [pii]. pmid:30763536
  231. 231.
    Payne RJH, Jansen VAA. Phage remedy: The peculiar kinetics of self-replicating prescription drugs. Clin Pharmacol Ther. 2000;68(3):225–230. pmid:11014403
  232. 232.
    Abedon ST. Phage remedy dosing: the issue(s) with multiplicity of an infection (MOI). Bacteriophage. 2016;6(3):e1220348. pmid:27738558
  233. 233.
    Bogovazova GG, Voroshilova NN, Bondarenko VM, Gorbatkova GA, Afanas’eva EV, Kazakova TB, et al. [Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages]. [Russian]. Zh Mikrobiol Epidemiol Immunobiol. 1992(3):30–33.
  234. 234.
    Capparelli R, Ventimiglia I, Roperto S, Fenizia D, Iannelli D. Number of an Escherichia coli O157:H7 bacteriophage for persistence within the circulatory system of mice contaminated experimentally. Clin Microbiol Infect. 2006;12(3):248–253.
  235. 235.
    Kumari S, Harjai Okay, Chhibber S. Isolation and characterization of Klebsiella pneumoniae particular bacteriophages from sewage samples. Folia Microbiol. 2010;55(3):221–227. pmid:20526833
  236. 236.
    Tiwari BR, Kim S, Rahman M, Kim J. Antibacterial efficacy of lytic Pseudomonas bacteriophage in regular and neutropenic mice fashions. J Microbiol. 2011;49(6):994–999. pmid:22203564
  237. 237.
    Dhungana G, Nepal R, Regmi M, Malla R. Pharmacokinetics and pharmacodynamics of a novel virulent Klebsiella phage Kp_Pokalde_002 in a mouse mannequin. Entrance Cell Infect Microbiol. 2021;11:684704. pmid:34485172
  238. 238.
    Rani SA, Pitts B, Beyenal H, Veluchamy RA, Lewandowski Z, Davison WM, et al. Spatial patterns of DNA replication, protein synthesis, and oxygen focus inside bacterial biofilms reveal numerous physiological states. J Bacteriol. 2007;189(11):4223–4233. pmid:17337582
  239. 239.
    Abedon ST. Phage “delay” in the direction of enhancing bacterial escape from biofilms: a extra complete manner of viewing resistance to bacteriophages. AIMS Microbiol. 2017;3(2):186–226. pmid:31294157
  240. 240.
    Eriksen RS, Svenningsen SL, Sneppen Okay, Mitarai N. A rising microcolony can survive and assist persistent propagation of virulent phages. Proc Natl Acad Sci U S A. 2018;115(2):337–342. pmid:29259110
  241. 241.
    Testa S, Berger S, Piccardi P, Oechslin F, Resch G, Mitri S. Spatial construction impacts phage efficacy in infecting dual-strain biofilms of Pseudomonas aeruginosa. Communications Biology. 2019;2(1):1–12.
  242. 242.
    Azeredo J, García P, Drulis-Kawa Z. Focusing on biofilms utilizing phages and their enzymes. Curr Opin Biotechnol. 2021;68:251–61. S0958-1669(21)00030-6 [pii]. pmid:33714050
  243. 243.
    Pires DP, Meneses L, Brandao AC, Azeredo J. An summary of the present state of phage remedy for the therapy of biofilm-related infections. Curr Opin Virol. 2022;53:101209. S1879-6257(22)00016-5 [pii]. pmid:35240424
  244. 244.
    Payne RJH, Jansen VAA. Pharmacokinetic rules of bacteriophage remedy. Clin Pharmacokinet. 2003;42(4):315–325. pmid:12648024
  245. 245.
    Nilsson AS. Pharmacological limitations of phage remedy. Ups J Med Sci. 2019;124(4):218–227. pmid:31724901
  246. 246.
    Leitner L, Sybesma W, Chanishvili N, Goderdzishvili M, Chkhotua A, Ujmajuridze A, et al. Bacteriophages for treating urinary tract infections in sufferers present process transurethral resection of the prostate: a randomized, placebo-controlled, double-blind scientific trial. BMC Urol. 2017;17(1):90. pmid:28950849
  247. 247.
    Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Improvement and use of customized bacteriophage-based therapeutic cocktails to deal with a affected person with a disseminated resistant Acinetobacter baumannii an infection. Antimicrob Brokers Chemother. 2017;61(10):e00954–e00917. pmid:28807909
  248. 248.
    Miller H. Phage remedy: legacy of CF advocate Mallory Smith endures. Cystic Fibrosis Information As we speak. 2021 (Might 27).
  249. 249.
    CF basis awards $1 Million to Felix Biotechnology to develop novel phage remedy [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  250. 250.
    Phage Australia [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  251. 251.
    Monash Phage Foundry [Internet]. Monash College; c2022 [cited 2023 Apr 4]. Out there from:
  252. 252.
    Phage WA [Internet]. Wal-yan Respiratory Analysis Centre; c2022 [cited 2023 Apr 4]. Out there from:
  253. 253.
    The Adelaide Phage Remedy Centre [Internet]. AusHealth; c2022 [cited 2023 Apr 4]. Out there from:
  254. 254.
    Coordination group for Bacteriophage remedy Leuven (CBL) [Internet]. UZ Leuven; c2022 [cited 2023 Apr 4]. Out there from:
  255. 255.
    Queen Astrid Army Hospital [Internet]. Bacteriophage Information; c2022 [cited 2023 Apr 4]. Out there from: https://www.bacteriophage.information/database/queen-astrid-military-hospital/.
  256. 256.
    Farncombe Phage [Internet]. McMaster College; c2020 [cited 2023 Apr 4]. Out there from:
  257. 257.
    P.H.A.G.E. [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  258. 258.
    Kiljunen SJ, Tervonen J, Skurnik M. Sensible points in establishing and sustaining a set of therapeutic bacteriophages: The Finnish expertise. In: Coffey A, Buttimer C, editors. Bacterial Viruses: Exploitation for Biocontrol and Therapeutics. Caister Tutorial Press; 2020. p. 645–662.
  259. 259.
    Phage Remedy [Internet]. Reference Middle for Advanced Osteo-Articular Infections; c2022 [cited 2023 Apr 4]. Out there from:
  260. 260.
    Eliava Consortium [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  261. 261.
    Nationales Zentrum für Phagen-Therapie [National Center for Phage Therapy] [Internet]. Medizinische Hochschule Hannover; c2022 [cited 2023 Apr 4]. Out there from:
  262. 262.
    Vitalis Phage Remedy [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  263. 263.
    Yerushalmy O, Khalifa L, Gold N, Rakov C, Alkalay-Oren S, Adler Okay, Ben-Porat S, Kraitman R, Gronovich N, Shulamit GK, Abdalrhman M, Coppenhagen-Glazer S, Nir-Paz R, Hazan R. The Israeli phage financial institution (IPB). Antibiotics (Basel). 2020;9(5). pmid:32455557
  264. 264.
    Phage Remedy Unit of the Medical Centre of the Institute of Immunology and Experimental Remedy PAS [Internet]. Hirszfeld Institute of Immunology and Experimental Remedy; c2022 [cited 2023 Apr 4]. Out there from:
  265. 265.
    phageSuisse [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  266. 266.
    Centre for Phage Analysis [Internet]. College of Leicester; c2023 [cited 2023 Apr 4]. Out there from:
  267. 267.
    UK Phage Remedy [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  268. 268.
    Middle for Modern Phage Functions and Therapeutics [Internet]. College of California San Diego College of Medication; c2022 [cited 2023 Apr 4]. Out there from:
  269. 269.
    Middle for Phage Biology and Remedy at Yale [Internet]. Nameless; c2022 [cited 2023 Apr 4]. Out there from:
  270. 270.
    Middle for Phage Expertise [Internet]. Texas A&M College; c2022 [cited 2023 Apr 4]. Out there from:
  271. 271.
    Tailor-made Antibacterials and Modern Laboratories for Phage (Φ) Analysis [Internet]. Baylor Faculty of Medication; c2022 [cited 2023 Apr 4]. Out there from:
  272. 272.
    Djebara S, Maussen C, De VD, Merabishvili M, Damanet B, Pang KW, et al. Processing phage remedy requests in a Brussels navy hospital: classes recognized. Viruses 2019;11(3):265. pmid:30884879
  273. 273.
    Elevating consciousness of phage remedy amongst physicians [Internet]. Hardy A; c2019 [cited 2023 Apr 4]. Out there from: https://phage.listing/capsid/raising-awareness-among-doctors.
  274. 274.
    Kuchment A. The Forgotten Treatment: The Previous and Way forward for Phage Remedy. New York: Springer.
  275. 275.
    Jones EH, Letarov AV, Clokie M. Neat science in a messy world: the worldwide affect of human habits on phage remedy, previous and current. Phage (New Rochelle). 2020;1(1):16–22. pmid:36147613
  276. 276.
    Nicolaou KC, Rigol S. A short historical past of antibiotics and choose advances of their synthesis. J Antibiot (Tokyo). 2018;71(2):153–184. pmid:28676714
  277. 277.
    Patents for proteins & peptides: threading the needle between patent eligibility and written description [Internet]. Pascal E; c2015 [cited 2023 Apr 4]. Out there from:
  278. 278.
    Todd Okay. The promising viral menace to bacterial resistance: The unsure patentability of phage therapeutics and the need of different incentives. Duke Legislation J. 2018;68:767.
  279. 279.
    AmpliPhi Biosciences to be ranted European patent protecting the usage of phage remedy to resensitize bacterial infections to antibiotics [Internet]. businesswire; c2016 [cited 2023 Apr 4]. Out there from:
  280. 280.
    Holtappels D, Lavigne R, Huys I, Wagemans J. Safety of phage purposes in crop manufacturing: a patent panorama. Viruses. 2019;11(3):277. pmid:30893844
  281. 281.
    Schmidt C. Phage remedy’s newest makeover. Nat Biotechnol. 2019;37(6):581–586. pmid:31068679
  282. 282.
    Ousterout DG, Selle Okay, inventors. 2020. Phage compositions comprising CRISPR-Cas techniques and strategies of use thereof. United States patent software WO2021092254A1.
  283. 283.
    Locus Biosciences broadcasts $35 million financing. GlobeNewswire [Internet]. Nameless. c2022 [cited 2023 Apr 4]. Out there from:
  284. 284.
    Luong T, Salabarria AC, Roach DR. Phage remedy within the resistance period: The place will we stand and the place are we going? Clin Ther. 2020;42(9):1659–1680. S0149-2918(20)30348-9 [pii]. pmid:32883528
  285. 285.
    Sacher JC, Zheng J, Lin RCY. Information to energy precision phage remedy: a have a look at the Phage Listing-Phage Australia partnership. Phage (New Rochelle). 2022;3(2):112–115. pmid:36157289
  286. 286.
    Gordillo Altamirano FL, Barr JJ. Phage remedy within the postantibiotic period. Clin Microbiol Rev. 2019 32(2):e00066–18. pmid:30651225
  287. 287.
    Leitner L, Ujmajuridze A, Chanishvili N, Goderdzishvili M, Chkonia I, Rigvava S, et al. Intravesical bacteriophages for treating urinary tract infections in sufferers present process transurethral resection of the prostate: a randomised, placebo-controlled, double-blind scientific trial. Lancet Infect Dis. 2021;21(3):427–436. pmid:32949500
  288. 288.
    McCallin S, Brüssow H. Medical trials of bacteriophage therapeutics. In: Harper DR, Abedon ST, Burrowes BH, McConville ML, editors. Bacteriophages: Biology, Expertise, Remedy. New York Metropolis: Springer Nature Switzerland AG; 2021. p. 1099–1129.
  289. 289.
    Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage therapy of intransigent diabetic toe ulcers: a case collection. J Wound Care. 2016;25(Suppl 7):S27–S33.
  290. 290.
    Ventola CL. The antibiotic resistance disaster: half 1: causes and threats. P T. 2015;40(4):277–283. pmid:25859123

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles